The presence of Clostridium difficile on environmental surfaces in healthcare facilities pre- and post-decontamination of patient rooms by Trice, Theresa
UNLV Theses, Dissertations, Professional Papers, and Capstones
8-1-2015
The presence of Clostridium difficile on
environmental surfaces in healthcare facilities pre-
and post-decontamination of patient rooms
Theresa Trice
University of Nevada, Las Vegas, theresa.trice@unlv.edu
Follow this and additional works at: http://digitalscholarship.unlv.edu/thesesdissertations
Part of the Environmental Sciences Commons, Molecular Biology Commons, and the Public
Health Commons
This Thesis is brought to you for free and open access by Digital Scholarship@UNLV. It has been accepted for inclusion in UNLV Theses, Dissertations,
Professional Papers, and Capstones by an authorized administrator of Digital Scholarship@UNLV. For more information, please contact
digitalscholarship@unlv.edu.
Repository Citation
Trice, Theresa, "The presence of Clostridium difficile on environmental surfaces in healthcare facilities pre- and post-decontamination
of patient rooms" (2015). UNLV Theses, Dissertations, Professional Papers, and Capstones. 2501.
http://digitalscholarship.unlv.edu/thesesdissertations/2501
 
  
THE PRESENCE OF CLOSTRIDIUM DIFFICILE ON 
ENVIRONMENTAL SURFACES IN HEALTHCARE 
FACILITIES PRE- AND POST-DECONTAMINATION  
OF PATIENT ROOMS 
By 
 
Theresa Lynn Trice 
Bachelor of Science in Biology 
University of Nevada, Reno 
2011 
 
A thesis submitted in partial fulfillment of the requirements for the  
Master of Public Health 
 
Department of Environmental and Occupational Health 
School of Community Health Sciences 
Division of Health Sciences 
The Graduate College 
 
University of Nevada, Las Vegas 
August 2015 
  
ii 
 
  
 
Thesis Approval 
The Graduate College 
The University of Nevada, Las Vegas 
        
July 1, 2015
This thesis prepared by  
Theresa Lynn Trice 
entitled  
The Presence of Clostridium difficile on Environmental Surfaces in Healthcare Facilities 
Pre- and Post-Decontamination of Patient Rooms 
is approved in partial fulfillment of the requirements for the degree of 
Master of Public Health –Environmental and Public Health 
Department of Environmental and Public Health 
 
                
Mark Buttner, Ph.D.       Kathryn Hausbeck Korgan, Ph.D. 
Examination Committee Chair     Graduate College Interim Dean 
 
Patricia Cruz, Ph.D. 
Examination Committee Member 
        
Timothy Bungum, Dr. PH 
Examination Committee Member 
 
Howard Gordon, Ph.D. 
Graduate College Faculty Representative 
 
iii 
 
ABSTRACT 
The presence of Clostridium difficile on environmental surfaces in healthcare 
facilities pre- and post-decontamination of patient rooms 
By 
Theresa Lynn Trice 
Mark Buttner, Ph.D., Advisory Committee Chair 
Professor, Department of Environmental and Occupational Health 
School of Community Health Sciences 
University of Nevada, Las Vegas 
 
Healthcare-associated infections (HAIs) are infections related to receiving 
medical care.  HAIs are responsible for an excess of morbidity and mortality among 
hospitalized patients.  Though most HAIs rates are on the decline, Clostridium difficile 
infection rates are at an all-time high, primarily due to the persistence of C. difficile 
spores in the environment.  In the United States, Clostridium difficile-related mortality 
rates per million have increased from 5.7 in 1999 to 23.7 in 2004, with an estimated 
26,642 deaths due to Clostridium difficile infections (CDIs).  Clostridium difficile is 
transmitted via the fecal-oral route or aerosolized endospores, but it can also be 
transmitted from high touch surfaces in healthcare facilities, such as door handles, bed 
rails, and bed pans contaminated with C. difficile spores.  Various methods of detection 
have been established since the 1970s, but they have limitations, such as cost, time, and 
availability.  The use of a molecular method of detection, such as polymerase chain 
reaction (PCR), could provide more rapid and sensitive results for the detection of 
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Clostridium difficile.  The objective of this study was to determine the presence of 
Clostridium difficile pre- and post-decontamination of patients’ rooms in a healthcare 
facility environment using culture and PCR analysis of surface samples.  No culturable C. 
difficile were detected; however, the culture analysis results showed a significant 
difference between the number of facultative and anaerobic bacteria in pre-
decontamination samples and post-decontamination samples (Z = -5.852, p = 0.000).  Of 
the 128 samples tested using PCR analysis, five samples were positive for Clostridium 
difficile DNA (3.9%); three were from pre-decontamination samples and two were from 
post-decontamination samples.  Reducing the rate of transmission of Clostridium difficile 
infections in hospitals is dependent on a number of factors (e.g., proper use of antibiotics, 
environmental decontamination, and proper hand-hygiene).  The results of this study 
indicate decontamination methods used at these facilities were effective in preventing 
environmental contamination of hospital rooms with facultative and anaerobic bacteria 
such as, C. difficile. 
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 CHAPTER 1 
BACKGROUND 
 From birth, individuals are continuously colonized with microorganisms 
throughout the gastrointestinal tract.  The normal human flora is complex in nature, yet 
crucial to an individual’s health.  Approximately 1,000 species of bacteria can be found 
in the gastrointestinal tracts of humans (Jernberg, Lofmark, Edlund, & Jansson, 2010).   
These bacteria interact and contribute to physiological processes of the body, such as the 
immune system (Jernberg et al., 2010).  The normal human flora is influenced by age, 
health status, and diet.  Despite the importance of the gut microbiota, some of these 
bacteria are potentially pathogenic.  The normal flora of an individual is believed to be a 
protective barrier against unwanted microorganisms; however, antibiotic use can lead to a 
disruption in the protective barrier of the gut microbiota.  This allows potentially 
pathogenic bacteria to proliferate in the gut and can result in an increase in toxicogenic 
bacteria and antibiotic resistant bacteria (Guarner & Malagelada, 2003; Jernberg et al., 
2010). 
Since the late 1940s, gastrointestinal complications have been associated with the 
use of antibiotics.  In the first thirty years of antibiotic use, most gastrointestinal 
complications were believed to be caused by the microorganism, Staphylococcus aureus 
(Bartlett, 2010).  During the 1970s, after the introduction of the antibiotic, clindamycin, 
there was a noticeable increase in antibiotic-associated colitis, also referred to as 
clindamycin-associated colitis.  Physicians reported a 20% incidence of diarrhea in 
patients who received clindamycin and a 10% incidence of pseudomembranous colitis 
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(Luciano & Zuckerbraun, 2014).  It was not until 1978 when Bartlett and his colleagues 
determined Clostridium difficile to be the causative agent of clindamycin-associated 
colitis, which was later called antibiotic-associated pseudomembranous colitis (Luciano 
& Zuckerbraun, 2014).  The colonization of C. difficile was initially seen in patients 
using clindamycin; however, Clostridium difficile infections (CDIs) are associated with 
the use of antibiotics in general, but especially after the administration of clindamycin, 
cephalosporins, fluoroquinolones, and β-lactams (Luciano & Zuckerbraun, 2014; 
Surawicz, 2015; Walters & Zuckerbraun, 2014). 
Clostridium difficile is the most common cause of infectious hospital acquired 
diarrhea and is known to cause 10% to 35% of all cases of antibiotic-associated diarrhea 
(Khan & Elzouki, 2014).  Within the last two decades, the incidence of CDIs has 
increased significantly (To & Napolitano, 2014).  The incidence of CDIs has more than 
tripled from 1996 to 2005, and continued to increase through 2008 (Luciano & 
Zuckerbraun, 2014).  Recent data from 2008, documented 350,000 CDI cases at the time 
of discharge from acute care hospitals (Walters & Zuckerbraun, 2014).  Another concern 
with Clostridium difficile is the emergence of community-acquired CDIs.  These 
infections are becoming more common among younger individuals who are at low risk 
and lack the traditional risk factors associated with CDIs (Khanna, Pardi, Aronson, 
Kammer, & Baddour, 2012).  Most CDI cases occur in the United States, Canada, and 
Europe.  These outbreaks are attributed to the increased use of broad-spectrum 
antibiotics, the evolving demographics in hospitalized patients (elderly vs. young), 
contaminated hospital surfaces, community-acquired CDIs, and the emergence of the 
hypervirulent C. difficile strain, BI/NAP1/027 (Khan & Elzouki, 2014).  
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CHAPTER 2 
INTRODUCTION 
Healthcare Associated Infections 
 Healthcare-associated infections (HAIs), or hospital/nosocomial infections, occur 
in hospitals and other healthcare settings, and are considered infections that are not 
present or incubating at the time of patient admission (World Health Organization; WHO, 
n.d.).  Healthcare-associated infections are considered the most frequent adverse health 
event in healthcare settings (WHO, n.d.).  HAIs are accountable for an excess of 
morbidity and mortality among hospitalized patients annually (Office of Disease 
Prevention and Health Promotion, 2014).  In 2011, roughly 75,000 hospitalized patients 
with an HAI died during their hospitalization (Centers for Disease Control and 
Prevention; CDC, 2014).  Each year, these infections cost the U.S. health care system 
billions of dollars in excess healthcare costs, in addition to the thousands of lives lost.  
Hospital-onset Clostridium difficile infections (CDIs) are estimated to cost anywhere 
between $5000 to $7200 per case in annual excess healthcare costs (Walters & 
Zuckerbraun, 2014).  The national estimate in excess healthcare costs due to CDIs range 
from $897 million to $1.3 billion (Walters & Zuckerbraun, 2014).  A survey on acute 
care hospitals in the United States determined that 1 in 25 hospitalized patients have at 
least one HAI (CDC, 2014).  At any given time, 7 out of 100 hospitalized patients in 
developed countries will acquire at least one healthcare-associated infection during their 
hospitalization (WHO, n.d.).  In 2011, there were approximately 722,000 HAIs in acute 
care hospitals in the United States.  Of those HAI cases, about 123,000 were due to 
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gastrointestinal illness, which is the second most common HAI, after pneumonia (CDC, 
2014).  According to the Centers for Disease Control and Prevention (2013), while most 
HAIs are declining, one HAI in particular, Clostridium difficile infection, is on the rise.  
Clostridium difficile infections remains at an all-time high and has currently replaced 
methicillin-resistant Staphylococcus aureus (MRSA) as the most common HAI (Lessa, 
Gould, & McDonald, 2012).  Approximately 80% of all Clostridium difficile infections 
are HAIs, but community-acquired Clostridium difficile infections are becoming more 
common (Khan & Elzouki, 2014).  Millions of patients around the world are affected by 
HAIs each year (WHO, n.d.).  Healthcare-associated infections are not only emotionally 
devastating, but can also result in catastrophic medical and financial consequences. 
Epidemiology of Clostridium difficile Infections 
During the 1990s, the incidence of Clostridium difficile infections in acute care 
hospitals in the United States was relatively low, with a rate of 30 to 40 cases per 100,000 
(Kelly & LaMont, 2008).  According to the Agency of Healthcare Research and Quality, 
the amount of CDI cases at the time of patient discharge doubled in the United States 
during the early 2000’s from 139,000 to 301,200 cases (Walters & Zuckerbraun, 2014).  
Due to the increase in CDI incidence, the mortality rate increased from 5.7 to 23.7 deaths 
per million persons (Drekonja, 2014).  Since the 1990s, the rate of hospital discharges 
that list CDI as the main diagnosis increased from 3.82 per 1,000 discharges in 2000 to 
8.75 per 1,000 discharges in 2008.  This increase was most prevalent among patients 65 
years and older.  In 2009, the rate of CDI hospital discharges began stabilizing with a 
2.5% decrease, and the hospital discharge estimate decreased to 8.53 per 1,000 
discharges.  However, these hospital rates do not include CDI cases that are managed in 
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an outpatient setting without the need of hospitalization.  In 2006, Ohio made all inpatient 
and outpatient CDI reporting mandatory.  From this information the CDI burden in Ohio 
was generalized to the entire U.S. population, which suggested that 333,000 initial and 
145,000 recurrent healthcare facility-onset CDI cases occur annually within the United 
States (Lessa et al., 2012). 
 Data collected from 28 community hospitals in the southern United States have 
suggested that Clostridium difficile is 21% more common than methicillin-resistant 
Staphylococcus aureus (Weber, Anderson, Sexton, & Rutala, 2013).  Vital records within 
the United States specify that the number of deaths with C. difficile enterocolitis listed as 
the primary cause of death increased from 793 in 1999 to 7,483 in 2008. The age-
adjusted death rate for C. difficile showed a 15% increase from 2007 to 2008 (Lessa et 
al., 2012).  As of 2008, a total of 93% of deaths from C. difficile occurred in those 65 
years and older, and CDI was reported as the 18
th
 leading cause of death in this age 
group.  In 2014, Clostridium difficile was estimated to cause more than 500,000 
infections per year (Walters & Zuckerbraun, 2014).  As the morbidity and mortality rates 
increase for CDIs it is more important than ever to alleviate the burden of this infection. 
Despite the high rates of hospital-acquired CDIs, community-acquired CDIs are 
becoming more common, accounting for more than one-third of all CDIs (Leffler & 
Lamont, 2011).  In 1994, the incidence of community-acquired C. difficile infections was 
estimated at less than 7 per 100,000 patients per year.  More recent data from 2005 
suggest that community-acquired CDIs have increased to roughly 40 cases per 100,000 
persons (Leffler & Lamont, 2011). 
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Clostridium difficile 
Clostridium difficile is an anaerobic, gram-positive, spore forming rod (van den 
Berg, Vaessen, Endt, Schülin, van der Vorm, & Kuijper, 2007).  Hall and O’Toole first 
isolated Clostridium difficile in 1935 from meconium and feces of newborn infants (Khan 
& Elzouki, 2014).  While most vegetative cells are susceptible to environmental stressors, 
bacterial endospores can survive in harsh environments. One of the most important 
events for C. difficile infection and disease transmission is sporulation.  The production 
of endospores allows Clostridium difficile to remain dormant in the environment for a 
prolonged period of time without the necessary nutrients for survival.  Once the 
environment becomes more favorable, C. difficile becomes vegetative and capable of 
causing infection.  Clostridium difficile endospores are resistant to the gastric acid within 
the stomach and will germinate once they reach the bowel (To & Napolitano, 2014).  
Certain characteristics of C. difficile promote environmental survival and transmission, 
which include sporulation, a low infectivity dose, and resistance to disinfectants (Weber 
et al., 2013).  Although vegetative C. difficile cells can only survive for 15 minutes in dry 
environments, endospores are persistent for five months in the environment (Weber et al., 
2013). 
 Since the 1990’s, the severity of CDIs has increased due to the increase in 
virulence.  The frequency and severity of CDIs is the result of the hypervirulent 
Clostridium difficile strain, BI/NAP1/027 or NAP-1/027.  This particular strain has been 
linked to changes in CDI disease pathogenesis in the United States, Canada, and Europe 
(Walters & Zuckerbraun, 2014).  NAP-1/027 has been known to cause increased 
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mortality in those experiencing fulminant colitis and has been recovered from more than 
35% of all CDI cases (Walters & Zuckerbraun, 2014).  Clostridium difficile strain NAP-
1/027 has mutations in the tcdC gene that inhibit toxin transcription.  A mutation in this 
regulatory gene leads to toxin production 10 times greater than less virulent strains 
(Walters & Zuckerbraun, 2014).  This particular strain also has higher rates of 
germination and sporulation, which is known to contribute to the virulence factor. 
Pathogenesis of Clostridium difficile 
The normal gut flora of an individual is the first line of defense against infection.  
However, after antibiotic treatment, the normal gut flora is depleted, allowing C. difficile 
to proliferate and adhere to host tissue.  Adhesion is an important mechanism for the full 
expression of virulence in a microorganism (Borriello, 1998).  The pathogenicity of 
Clostridium difficile is dependent on the production of two toxins, enterotoxin A (tcdA) 
and cytotoxin B (tcdB) (van den Berg, Juijper, Bruijnesteijn van Coppenraet, & Claas, 
2006).  Approximately, 50% to 60% of C. difficile strains are considered toxicogenic.  
The majority of C. difficile strains produce both toxin A and B, but 1% to 2% only 
produce toxin B (Bartlett, 2010).   
Toxins A and B are transcribed from a 19.6 kb pathogenicity locus that consists of 
five genes: Toxin A and B, and three regulatory genes.  Of the three regulatory genes, 
tcdR is a positive regulator of transcription; tcdC inhibits toxin transcription, while the 
role of tcdE is uncertain.  It is believed that tcdE facilitates the release of toxins by lysing 
the cytoplasmic membrane (Kelly & LaMont, 2008).  Toxin A was generally regarded as 
the most important factor causing enteropathogenic disease; however, recently there has 
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been an increase in toxin A negative, toxin B positive disease-causing C. difficile strains 
(van den Berg, et al., 2006).  It is more evident that toxin B is an essential element for the 
onset of CDI (Bartlett, 2010).  In non-toxicogenic strains of C. difficile, the pathogenicity 
locus is replaced with 127 bases of non-coding DNA (Borriello, 1998). 
Toxin A acts primarily on the intestinal epithelium, which triggers the immune 
response causing local tissue damage or necrosis, fluid secretion, and inflammation 
(Khan & Elzouki, 2014).  Toxin B signals the release of cytotoxins causing the 
destruction of the cytoskeleton, which supports cell function.  Toxin B is considered 
1,000 times more potent than toxin A (To & Napolitano, 2014).  Toxins A and B are 
internalized after binding to receptors of the large bowel.  The toxins then disrupt 
intracellular signaling pathways regulated by Rho GTPases, a family of small signaling G 
proteins.  Toxins A and B disrupt the integrity of the colon by activating epithelial cell 
apoptosis, which recruits polymorhponuclear neutrophils to the site of toxin action.  In 
the presence of polymorhponuclear neutrophils, CDIs are then considered 
pseudomembranous colitis (Khan & Elzouki, 2014). 
Clinical Manifestations 
Clostridium difficile infections occur almost exclusively in the large bowel (Voth 
& Ballard, 2005).  Clostridium difficile is the causative agent of antibiotic-associated 
diarrhea (CDAD), pseudomembranous colitis (PMC), and toxic megacolon (O’Neill, 
Ogunsola, Brazier, & Duerden, 1996).  However, CDIs can also progress to fulminant 
colitis, which is often due to poor medical management (Walters & Zuckerbraun, 2014).  
Fulminant colitis refers to the sudden and quick onset of colitis.  It is considered so 
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intense and severe that it can lead to death.  Fulminant colitis only occurs in about 5% of 
CDI patients, but is associated with a mortality rate of 35% to 80% (Walters & 
Zuckerbraun, 2014).  Patients who develop diarrhea or colitis during or after treatment 
with an antibiotic are believed to have C. difficile-induced diarrhea or colitis (Kato, Ou, 
Kato, Bartley, Brown, Dowell, & Ueno, 1990).   
The disease associated with Clostridium difficile can range from mild self-limiting 
diarrhea to severe diarrhea, PMC, and fulminant colitis which can be fatal (Khan & 
Elzouki, 2014; Noren, 2010).  The onset of CDI symptoms is often sudden and an 
individual will experience watery, foul-smelling diarrhea, as well as abdominal pain, 
elevated white blood cell counts, and possible fever (Borriello, 1998).  Mild cases of 
CDIs are defined by three or more loose stools in a 24 hour period and are generally self-
limiting, but for cases that persist symptoms will worsen and can result in fulminant 
colitis (Noren, 2010; To & Napolitano, 2014).  Fulminant colitis is characterized by PMC 
with white fibrin-covered protrusions throughout the colonic wall (Noren, 2010).  
Fulminant colitis and PMC can lead to multiple organ dysfunction syndrome and 
ultimately death (To & Napolitano, 2014).  Severe cases of CDI may show improvement 
after diarrhea has resolved, but this is often a sign of paralytic ileus or toxic megacolon 
(Khan & Elzouki, 2014; Noren, 2010).   
Diagnosing Clostridium difficile Infections 
 Since the 1970s, scientists have been discovering ways to identify and diagnose 
CDIs.  The cytotoxin assay was the initial test used to diagnose CDIs in 1978.  The 
cytotoxin assay is about 95% sensitive and 98% specific for detecting CDI in patients 
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with pseudomembranous colitis, making it the gold standard for C. difficile detection.  
Although the cytotoxin test is considered the standard, there are some disadvantages 
associated with this test.  This test is considered a demanding and expensive test, which 
generally takes about 24 to 72 hours to obtain results, and the reagents are not readily 
available.  Despite the fact that there are faster, easier, and less expensive ways to 
diagnose CDIs, the cytotoxin assay is still the gold standard (Bartlett, 2010). 
 The latex agglutination assay (LAT) was introduced in the early 1980s to detect 
the Clostridium difficile toxin A.  However, it did not actually detect the toxin it was 
designed to detect; instead, it detected a protein of C. difficile.  The LAT is now 
commercially available to detect C. difficile itself and not toxin A.  The LAT is typically 
used in combination with the enzyme immunoassay (EIA) to detect CDIs.  The EIA test 
for the diagnosis of Clostridium difficile was also introduced in the 1980s.  The EIA test 
is used to detect C. difficile toxins, as well as C. difficile itself.  It is used to detect either 
toxin A or the combination of toxin A and B.  Presently, testing for both toxins A and B 
is preferred over toxin A alone.  The EIA test has become the most frequently used CDI 
detection method in the U.S. and the world due to its rapid results, and relatively low 
cost.  Some of the disadvantages surrounding this test include decreased sensitivity 
resulting in possible false-negatives (Bartlett, 2010). 
 The culture-toxin test is rarely used in U.S. laboratories.  This test requires 
alcohol-shocked or heat-shocked stool to select for Clostridia.  The cultures are 
incubated, and then tested for C. difficile toxins.  This test is highly sensitive and is also 
considered a gold standard for CDI diagnosis.  As with any detection method, the culture-
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toxin test can also result in false-positives (Bartlett, 2010).  The most recent test 
introduced for the detection of C. difficile toxins is polymerase chain reaction (PCR).  
PCR detects the genes responsible for the production of C. difficile toxin A and B.  It is 
advantageous because it provides quick results, and PCR reagents from commercial 
sources are readily available.  The greatest advantage of PCR testing is the high 
sensitivity of PCR technology (Bartlett, 2010).  However, PCR cannot distinguish 
between viable and nonviable cells, and inhibition can limit the detection of positive 
samples. 
The United States currently uses EIAs for toxin A and B, but it will eventually be 
replaced by Glutamate Dehydrogenase (GDH)-based combination tests or PCR for the 
detection of toxicogenic Clostridium difficile.  GDH-based combination tests detect the 
GDH enzyme, which is produced in significantly higher quantities than the C. difficile 
toxin itself and yields a more sensitive assay than toxin EIAs.  However, GDH detection 
does not distinguish between toxicogenic and non-toxicogenic C. difficile strains 
(Bassetti, Villa, Pecori, Arzese, & Wilcox, 2012).  GDH-based combination tests are a 
highly specific assay that can rule out the presence of C. difficile in stool samples 
(Goldenberg, Cliff, & French, 2010).  GDH-based combination tests and PCR are rapid, 
sensitive, and specific within noted limitations (Bartlett, 2010). 
Treating Clostridium difficile Infections 
 The first step in treating a CDI is to stop all current antibiotic treatments and 
provide supportive care, such as electrolyte replacement.  A Clostridium difficile 
infection can be treated with the use of CDI specific antibiotics.  Oral vancomycin and 
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metronidazole are the most commonly used antibiotics to treat CDIs (Bartlett, 2010).  
These antibiotics tend to be equally effective; however, patients with a more serious case 
of CDI respond better to oral vancomycin because oral vancomycin goes directly to the 
site of infection (Bartlett, 2010).  In recent years, CDIs were showing an increased 
resistance to fluoroquinolones.  Any previous use of fluoroquinolones or clindamycin to 
treat a CDI is now correlated with the development of high-level C. difficile resistance to 
those antibiotics (Keller, 2010). 
Treatment for CDIs is based on the severity of infection.  Mild to moderate CDIs 
are treated with 500 mg oral metronidazole, taken three times a day for 10 days.  Severe 
CDIs require 125 mg oral vancomycin, taken four times a day for 10 days.  Severe-
complicated CDIs are treated with 500 mg intravenous metronidazole every 8 hours and 
125 to 500 mg of oral vancomycin four times a day.  In the presence of ileus or 
abdominal distention, the administration of 500 mg vancomycin in 500 ml of saline per 
rectum four times a day is required (Luciano & Zuckerbraun, 2014).   
In 2011, the U.S. Food and Drug Administration approved fidaxomicin for use in 
the treatment of CDIs, and studies have shown a decrease in the recurrence of CDIs 
compared with vancomycin use (Ritter & Petri, 2013).  Fidaxomicin is one of the first 
RNA polymerase inhibiting antibiotics with a very narrow spectrum of antibiotic activity 
(Hostler & Chen, 2013).  Fidaxomicin is effective against Clostridium difficile and C. 
perfringens.  This particular antibiotic has little to no activity on the normal enteric flora 
(Hostler & Chen, 2013).  Fidaxomicin is administered in doses ranging between 100 to 
400 mg/day for 10 to 48 days, depending on CDI severity.  Clostridium difficile 
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infections were cured 100% of the time in individuals receiving 400 mg of fidaxomicin 
per day (Hostler & Chen, 2013). 
Recurrent Clostridium difficile Infections 
Recurrent CDIs are infections that occur within 8 to 12 weeks of a previous 
infection due to the altered microbial flora within the gastrointestinal tract (Luciano & 
Zuckerbraun, 2014; Surawicz, 2015).  An estimated 10% to 25% of patients develop 
recurrent CDIs within 12 weeks of the initial CDI (Luciano & Zuckerbraun, 2014).  
Treatment for first recurrent CDI is the same as an initial CDI.  A second recurrent CDI 
requires a pulsed and tapered vancomycin treatment consisting of 125 mg of oral 
vancomycin for seven weeks.  A third episode of CDI can be treated with fecal 
microbiota transplantation or fecal microbiota therapy (FMT) in an attempt to recolonize 
the colonic flora (Drekonja, 2014; Luciano & Zuckerbraun, 2014). 
FMT consists of the infusion of healthy donor stool into the gastrointestinal tract 
of another individual to cure a specific illness (Aroniadis & Brandt, 2013).  The 
effectiveness of FMT is dependent on the relationship to the stool donor, the route of 
administration, the volume administered, and previous treatment.  FMT is effective in 
92% of patients with no adverse reactions (Walters & Zuckerbraun, 2014).  Several 
studies have shown that FMT has great therapeutic potential for CDIs (Aroniadis & 
Brandt, 2013); however, FMT has not been approved by the Food and Drug 
Administration (Luciano & Zuckerbraun, 2014).  The pharmaceutical company, Sanofi 
Pasteur, is currently developing an oral vaccine using nonpathogenic endospores to 
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stimulate C. difficile antigen immunity.  Clinical trials are expected to begin in 2015 
(Luciano & Zuckerbraun, 2014). 
CDI Risk Factors 
 The vast majority of CDI cases are seen in individuals on antibiotic treatments, 
those undergoing medical procedures, hospitalized patients, elderly patients, and 
individuals with compromised immune systems.  However, the risk for CDIs in patient 
populations that were previously unrecognized has increased.  More recent cases of CDIs 
have shown an increased morbidity in patients not receiving antibiotics, pediatric 
patients, pregnant women, and community-acquired CDIs (Bartlett, 2010; Khan & 
Elzouki, 2014).   
The most important risk factor for CDIs is the recent administration of antibiotics, 
within the last three months.  All antibiotics have been linked to CDIs; however, 
clindamycin, fluoroquinolones, cephalosporins, and β-lactams are most often implicated 
in CDIs (Luciano & Zuckerbraun, 2014; Surawicz, 2015; Walters & Zuckerbraun, 2014).  
Frequent use of broad-spectrum antibiotics is the most widely recognized modifiable risk 
factor (Walters & Zuckerbraun, 2014).  Antimicrobials that are active against anaerobic 
bacteria, such as Clostridium difficile, are considered the greatest risk for the 
development of a CDI because of their ability to alter gastrointestinal flora (Khan & 
Elzouki, 2014).  Other risk factors include age, the use of proton pump inhibitors, 
immunosuppressants, inflammatory bowel disease, recent surgery, nasogastric tube 
feeding, and prolonged hospitalization (Khan & Elzouki, 2014).   
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Community-acquired CDI cases are seen in individuals that did not receive 
antibiotic treatment prior to the development of symptoms (Khan & Elzouki, 2014).  The 
transmission of community-acquired CDIs is not widely studied, but it is believed to be 
transmitted through contaminated food and water.  Another theory suggests there is an 
increase in asymptomatic Clostridium difficile carriers, which leads to an increase in 
person-to-person transmission (Khanna et al., 2012) 
CDI Control and Prevention 
 Preventing CDIs is an ongoing challenge for healthcare facilities.  Infection 
control measures such as good hand-hygiene, early contact isolation, and barrier 
precautions are practiced to help alleviate the risk of CDI transmission (Surawicz, 2015).  
Environmental cleaning programs require the use of bleach-based disinfectants or EPA 
approved sporicidal disinfectants, which contain at least 5000 ppm chlorine (Luciano & 
Zuckerbraun, 2014; Surawicz, 2015).  Antibiotic stewardship programs can decrease the 
incidence of CDIs in hospitals by promoting the appropriate use of antimicrobials.  
Prompt CDI patient identification is a key factor in infection control because the majority 
of CDI patients will respond to antimicrobial therapy if the antimicrobials are 
administered promptly (Khan & Elzouki, 2014).  The United Kingdom’s National Health 
Service was able to reduce the rate of CDIs by 60% by limiting the use of broad-spectrum 
cephalosporins and fluoroquinolones in conjunction with other control and prevention 
measures (Luciano & Zuckerbraun, 2014). 
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Clostridium difficile on Environmental Surfaces 
Clostridium difficile is mainly transmitted via the fecal-oral route or aerosolized 
endospores, but it can be transmitted from patient-to-patient, healthcare worker-to-
patient, or from contaminated surfaces in the hospital, such as door handles, bed rails, and 
bed pans (Mutters, Nonnenmacher, Susin, Albrecht, Kropatsch, & Schumacher, 2008).  
In a hospital setting, there are three main modes of transmission aside from fecal-oral 
transmission (Figure 1).  The first mode of transmission is the direct transfer of C. 
difficile via hands to a non-infected patient.  The second mode of transmission is the 
transfer of C. difficile through the contaminated environment with direct inoculation into 
the mouth or into the colon.  The final mode of transmission is from the contaminated 
environment to a healthcare worker and the indirect transfer to a non-infected patient 
(Weber, Rutala, Miller, Huslage, & Sickbert-Bennett, 2010).   
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Figure 1. CDI modes of transmission (Weber et al., 2010) 
An infected individual with acute diarrhea may defecate 10
7
 or 10
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microorganisms per gram of stool (Mutters et al., 2008).  These microorganisms can 
contaminate the environment with vegetative cells and spores.  Asymptomatic carriers 
can also contribute to environmental contamination and may be one of the causes of 
endemic diseases in hospitals (Mutters et al., 2008).  There are between 1% and 2% of 
healthy adults who harbor C. difficile asymptomatically, and approximately 10% to 30% 
of hospitalized patients are colonized with this organism (Bartlett, 2010).  The prevalence 
of C. difficile spores in the environment is relatively high in long-term healthcare 
facilities and hospitals (Bartlett & Gerding, 2008).  The presence of C. difficile spores can 
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range between 10% and 15% in areas where infected patients are present (Mutters et al., 
2008).  Clostridium difficile spores are a major concern for HAIs because spores are not 
easily destroyed with regular decontamination procedures; therefore, they require special 
infection control strategies to avoid transmission throughout the hospital environment. 
Contaminated environmental surfaces are considered a potential source of 
transmission for many healthcare associated infections (Donskey, 2013).  Generally, 
surfaces in the surrounding area of an infected patient are more contaminated than more 
distant surfaces; however, patients with diarrhea can cause widespread contamination 
(Otter, Yezli, Salkeld, & French, 2013).  Numerous studies have shown that 
environmental surface cleaning interventions can not only increase the effectiveness of 
cleaning, but also reduce the amount of contamination on environmental surfaces 
(Donskey, 2013).  Ineffective decontamination after patient discharge can result in an 
increased risk of infection of the same pathogen in the next patient room occupant.  This 
has been shown for many microorganisms including, C. difficile, methicillin-resistant 
Staphylococcus aureus, vancomycin-resistant enterococci, and other multidrug-resistant 
microorganisms (Otter et al., 2013).  It is currently believed that environmental 
contamination contributes to the transmission of Clostridium difficile in a hospital setting 
(Weber et al., 2010). 
In a study conducted by Mutters et al. (2008), a total of 531 environmental 
samples were collected.  The environmental samples were collected and analyzed for the 
presence of C. difficile from the hands of patients and health care workers, toilets, beds, 
and other surfaces near the patients using a flocked swab.  These samples were then 
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classified into three different groups based on patient and hospital ward status for C. 
difficile. The three groups were: 1) C. difficile positive, ward positive, 2) C. difficile 
negative, ward positive, and 3) C. difficile negative, ward negative.  PCR analysis 
determined that the presence of C. difficile in the environment was greater near C. 
difficile patients.  In addition, the environment of C. difficile-positive patients had 
significantly higher counts of bacteria on the floor and the near environment (<40 inches) 
(Mutters et al., 2008). 
 Recently, the interest in Clostridium difficile has grown due to the considerable 
increase of CDI cases and the increase in morbidity and mortality (Bartlett, 2010).  
Important factors in controlling the rate of Clostridium difficile infection are through 
infection control, antibiotic control, and hand hygiene (Bartlett, 2010).  Determining the 
presence of Clostridium difficile spores in the hospital environment is important to 
evaluate decontamination protocols after a patient with a CDI is discharged.  Clostridium 
difficile spores are difficult to eliminate from the environment with detergent based 
cleaners (Mutters et al., 2008).  In addition, many healthcare facilities may not be 
cleaning rooms thoroughly.  One study showed that only 47% of high touch surfaces in 
three hospitals were being cleaned (Carling, Briggs, Perkins, & Highlander, 2005).  If 
healthcare facilities were able to eliminate C. difficile spores after a known case of CDI is 
discharged from the hospital, this would further reduce the risk of Clostridium difficile 
infections.  
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Objective 
The objective of this study was to determine the presence of Clostridium difficile 
in healthcare facility environments pre- and post-patient room decontamination.  
Environmental samples were collected from seven high touch surfaces (i.e., floor, call 
bell/TV remote, telephone, bathroom doorknob, toilet flush lever, bed rail, and bedside 
table) and analyzed using culture and real-time PCR analysis with species-specific 
primers and probes.  The results were used to assess the effectiveness of decontamination 
practices to reduce the prevalence of C. difficile in patient rooms. 
Research Questions and Hypotheses 
1) Will Clostridium difficile be detected on high touch environmental surfaces in the 
rooms of infected patients pre- and post-decontamination? 
2) Are the decontamination procedures used in healthcare facilities effective in reducing 
the prevalence of Clostridium difficile? 
Therefore, the proposed hypotheses were: 
H
1
0: There is no difference in the prevalence of Clostridium difficile on environmental 
surfaces pre- and post-decontamination of patient rooms.  
H
1
a: There is a difference in the prevalence of Clostridium difficile on environmental 
surfaces pre- and post-decontamination of patient rooms. 
H
2
0: There is no difference between the effectiveness of decontamination procedures used 
in healthcare facilities to reduce the prevalence of Clostridium difficile. 
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H
2
a: There is a difference between the effectiveness of decontamination procedures used 
in health care facilities to reduce the prevalence of Clostridium difficile. 
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CHAPTER 3 
MATERIALS AND METHODS 
Study Design 
This study was conducted at three healthcare facilities in Southern Nevada.  
Environmental swab surface samples were collected on six high touch surfaces from 
healthcare facilities in rooms of patients with diagnosed cases of C. difficile.  No patient 
identifying information was provided to UNLV personnel.  An Institutional Review 
Board (IRB) application was submitted and approved for exemption from IRB review 
(IRB Protocol # 1408-4890M; Appendix A).  Prior to patient room decontamination, 
seven surface samples were collected from high touch surfaces.  Following patient room 
decontamination, the seven corresponding post-decontamination samples were collected 
for a total of 14 samples per room (Figure 2).  A total of 10 rooms were sampled for a 
total of 128 environmental samples collected.  Following sample collection, the samples 
were processed and analyzed for the presence of Clostridium difficile using culture 
analysis and real-time PCR. 
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Figure 2. Study design flow chart  
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Sample Collection 
Pre-labeled sampling kits were distributed to the participating healthcare facilities 
along with environmental investigation data sheets (Appendix B).  Hospital personnel 
were trained in the procedures of the surface sampling protocol.  The environmental 
swabs and transport containers were pre-labeled with a number and letter designation to 
match the sample location and whether the sample was pre- or post-decontamination.  
The first set of surface samples were taken after patient discharge, pre-patient room 
decontamination using the Centers for Disease Control and Prevention’s (CDC) surface 
sampling procedures for Bacillus anthracis spores from smooth, non-porous surfaces 
(Appendix C).  The second set of environmental surface samples were taken post-patient 
room decontamination using the same method.  All environmental samples collected 
were stored at 4°C and transported within 24 hours to the Emerging Diseases Laboratory 
(EDL) at the University of Nevada, Las Vegas (UNLV) for analysis.  The high touch 
surfaces tested were determined based on previous research, and consisted of: the floor, 
call bell/TV remote, telephone, bathroom doorknob (inside and outside), toilet flush 
lever, bed rail, and bedside table (Mutters et al., 2008). 
Hospital Decontamination Methods 
Post patient discharge, patient room decontamination procedures required a 
systematic cleaning of rooms from cleanest to dirtiest surfaces.  Two facilities use the 
disinfectant, Dispatch®, which contains sodium hypochlorite (0.5%), to perform terminal 
cleaning.  One facility utilizes timed terminal cleaning, meaning hospital personnel clean 
surfaces for 45 minutes followed by disinfection using Dispatch®.  The other facility 
uses similar cleaning procedures; however, they do not utilize timed terminal cleaning 
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before disinfection with Dispatch®.  The third facility uses a quaternary ammonium 
compound for terminal cleaning followed by the use of a UV (Tru-D SmartUVC, 
Memphis, TN) light for 35 minutes.  Once terminal cleaning is completed, the UV light is 
then placed in the room to ensure the entire room and bathroom is exposed.  If it is not 
possible to cover the room and bathroom simultaneously, the light is run in each area for 
35 minutes separately. 
Sampling Methods 
The bed rail, call bell/TV remote, bathroom doorknobs, and toilet flush lever 
samples were collected from an area of 26 cm
2
 by trained hospital personnel using sterile, 
foam tipped swabs (Puritan ™, Guilford, ME).  All sterile swabs were transported in 10 
ml of neutralizing buffer (Hardy Diagnostic, Santa Maria, CA).  Wearing clean gloves, 
hospital personnel aseptically removed the sterile swab from the transport container and 
expressed any excess buffer using the side of the transport container.  Applying light 
pressure, the surface was swabbed in an overlapping ‘S’ pattern to cover the entire 
surface with horizontal strokes.  The swab was then rotated 180° and the same area was 
swabbed again using vertical ‘S’ strokes.  The head of the exposed swab was broken off 
into the transport container.  The floor and bedside table samples were collected from an 
area of 645 cm
2
 using sterile, sponge-sticks (3M™, St. Paul, MN).  Wearing clean 
gloves, hospital personnel aseptically removed the sterile sponge from the packaging and 
placed the sponge into a transport container where 10 ml of neutralizing buffer was added 
to moisten the sponge.  Applying light pressure, the surface was sampled using a push-
pull method in an overlapping ‘S’ pattern to cover the entire surface with horizontal 
strokes.  The sponge was then rotated 180° and the same area was sampled again using 
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vertical ‘S’ strokes.  Using the narrow side of the sponge, the area was sampled using 
diagonal ‘S’ strokes.  The perimeter of the sampling area was wiped using the tip of the 
sponge.  The head of the exposed sponge was broken off into the transport container.  
Upon completion of sample collection all samples were stored at 4°C until sample 
retrieval.  Sample analysis procedures were adapted from the Laboratory Response 
Network (LRN), Bacillus anthracis Spore Environmental Swab and Wipe Processing 
Procedure (2014). 
Sample Processing 
   Once the samples were transferred to the EDL at UNLV, all the samples were 
processed in the biological safety cabinet within 24 hours.  The sponges were transferred 
from the original specimen container to a sterile, labeled Stomacher® 80 bag (Seward 
Laboratory Systems Inc., Davie, FL) using sterile forceps.  Approximately 10 ml of 
neutralizing buffer was added to each stomacher bag (adapted from LRN, 2014).  The 
sponges were then homogenized on the high setting of a Stomacher® 80 for one minute 
(Seward Laboratory Systems Inc.).  From the outside of the bag, the sponges were moved 
to the top of the bag and the excess liquid was squeezed from the sponges.  Using sterile 
forceps, the sponges were removed from the stomacher bags and discarded in a biohazard 
bag.  The stomacher bags sat for 10 minutes to allow the elution suspension foam to 
settle.  Approximately 7 to 10 ml of neutralizing buffer was recovered from each sponge 
sample.  The sample was then divided for culturing, DNA extraction, and storing.  The 
elution suspension was gently mixed in the stomacher bag and 3 ml of the elution 
suspension was pipetted into a sterile, labeled 4 ml cryovial to be transferred to a local 
commercial laboratory for culture analysis (Forensic Analytical, Las Vegas, NV).  A 2 ml 
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aliquot of the elution suspension was pipetted into a sterile, labeled 2 ml microcentrifuge 
tube for concentration of the sample and DNA extraction.  An additional remaining 
elution suspension was pipetted into a sterile, labeled cryovials and stored at -20°C.   
 Swab samples were processed in a biological safety cabinet.  The handles of the 
swabs were cut off using sterile scissors for the swab to fit into a sterile, labeled 15 ml 
centrifuge tube.  The swabs were then vortexed in 10-second intervals for two minutes to 
dislodge spores from the swabs.  Excess fluid was expressed from the swabs and the 
swabs were then removed from the 15 ml centrifuge tubes using sterile forceps and 
discarded in a biohazard bag.  Approximately 9 ml of sample was recovered from each 
swab.  The elution suspension was vortexed and 3 ml of the elution suspension was 
pipetted into a sterile, labeled 4 ml cryovial for culturing.  Two milliliters of elution 
suspension was pipetted into a sterile, labeled 2 ml microcentrifuge tube for 
concentration of the sample and DNA extraction.  An additional 5 ml of the elution 
suspension was pipetted into a sterile, labeled 15 ml centrifuge tube and stored at -20°C.    
Culture Analysis 
 Approximately 3 ml of the processed C. difficile sample was transferred to 
Forensic Analytical Laboratories, Inc. (Las Vegas, NV).  For culture analysis, 100 µl was 
plated on tryptic soy agar (TSA; Hardy Diagnostic) and incubated at 37°C for 24 hours 
under anaerobic conditions.  Indicator strips were used to ensure no oxygen was present.  
Visible colony forming units (CFU) were then transferred to BioLog Universal Anaerobe 
(BUA; Oxyrase, Inc., Mansfield, OH) agar and incubated for an additional 24 to 48 
hours.  Colonies were then placed into AN inoculating fluid (BioLog, Hayward, CA) and 
placed on an anaerobic AN MicroPlate (BioLog), which was incubated for 24 to 48 hours 
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in anaerobic conditions.  The AN MicroPlate was then read by BioLog ELx808BLG 
software (BioTek Instruments, Inc., Winooski, Vermont) to identify the anaerobic 
colonies.  If the sample was negative for C. difficile, the CFU were classified as 
facultative bacteria or unrelated anaerobic bacteria.  Indicator strips were used to ensure 
no oxygen was present.  Results were reported as CFU/ml and converted to CFU/sample. 
DNA Extraction and Purification 
 For concentration of the sample, 2 ml was filtered through a 0.45 µm HAWG 
filter membrane (EMD Millipore, Billerica, MA) using a swinnex and a 10 ml sterile 
syringe.  The filter was then rinsed with 8 ml of 0.01M phosphate buffer with tween (pH 
7.0) and aseptically removed from the syringe and placed in a bead beater tube containing 
50 mg of 425-600 µm and ≤ 106 µm diameter glass beads to begin the DNA extraction 
process.  The DNA was extracted from the concentrated environmental samples using the 
Amicon DNA extraction and purification kit (EMD Millipore) following the 
manufacturer’s protocol.  Upon completion, this procedure provided approximately 100 
µl of DNA, which was stored at -70ºC for future use.  
Real-Time Polymerase Chain Reaction 
 PCR analysis of the DNA was conducted in duplicate using the 7900 HT Fast 
PCR System (Applied Biosystems, Foster City, CA).  Positive and negative controls were 
included with each PCR.  The primers and probe targeted a 157 base pair species-specific 
highly conserved region from the 16S rRNA gene sequence (Mutters et al., 2008).  The 
sequence of the forward primer was 5’TTGAGCGATTTACTTCGGTAAAGA3’and the 
sequence of the reverse primer was 5’CCATCCTGTACTGGCTCACCT3’.  A TaqMan®  
probe was used, and the sequence was as follows, 6-FAM-
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5’CGGCGGACGGGTGAGTAACG3’-TAMRA.  An internal positive control (IPC) was 
included in the reaction to test for inhibition in the samples (Applied Biosystems).  
Quantitative PCR (QPCR) was used to determine the concentration of the target gene in 
environmental samples.  QPCR standards consisted of serial dilutions with known C. 
difficile DNA (ATCC BAA-1871-D-5, ATCC, Manassas, VA) concentrations amplified 
in duplicate with environmental samples.  Each PCR reaction contained a total volume of 
25 μl, that included nuclease free water (Promega, Madison, WI), 1X of TaqMan® 
Universal PCR Master Mix (Applied Biosystems), 0.5 µM of the C. difficile forward 
primer (Eurofins MWG Operon, Huntsville, AL), 0.5 µM of the C. difficile reverse 
primer (Eurofins MWG Operon), 0.15 µM of the C. difficile probe (Applied Biosystems) 
and 5μl of template DNA.  The instrument was operated in standard mode with the 
following parameters: 2 min at 50°C, 10 min at 95°C, and 40 cycles of 15 sec at 95°C 
followed by 1 min at 60°C.  After amplification, the DNA was analyzed using the 7900 
HT Fast PCR system (Applied Biosystems).  The software constructed a standard curve 
of cycle threshold (CT) values versus DNA concentration.  The CT value is the number of 
PCR cycles required for detectable amplification and is inversely proportional to the 
concentration of DNA in the sample.  The standard curve was then used to determine the 
number of cells in the reaction and the number of cells per sample was calculated. 
Data Analysis 
 A total of 128 samples were collected from 10 rooms during this study.  The mean 
CFU were calculated before and after decontamination.  The percent reduction was also 
determined.  The data were analyzed using the Shapiro Wilks W test to test for normality 
of the distribution.  The data were then analyzed using a means comparison statistical 
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method dependent upon the distribution of the data.  The Wilcoxon Rank Sum test was 
the non-parametric statistical method used.  This statistical method is used to compare 
two matched samples, related samples, or repeated measurements on a sample that does 
not display a normal distribution.  This statistical method will determine whether the 
populations’ means differ pre- and post-decontamination of patient rooms.  Descriptive 
statistics were calculated using IBM SPSS Statistics version 22. 
  
31 
 
CHAPTER 4 
RESULTS 
Culture Analysis 
 A total of 128 samples were taken from 10 patient rooms, 65 pre-
decontamination and 63 post-decontamination (Table 1).  The detection limit for a 10 ml 
sample was estimated to be 100 colony forming units (CFU) per sample.  Pre-
decontamination samples had an average of 6,532 facultative CFU/sample.  Post-
decontamination samples had an average of 400 facultative CFU/sample.  No viable 
Clostridium difficile was detected on any of the surfaces tested.  Two related species, 
Ruminococcus torques and Fusobacterium nucleatum, from the class Clostridia were 
cultured from two of the 65 pre-decontamination samples.  There were no viable 
organisms in the class Costridia from the 63 post-decontamination samples.   
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The facultative bacteria CFU count were also analyzed to determine the 
effectiveness of patient room decontamination (Figure 3).  The bedside table had the 
highest CFU count pre-decontamination with an average of 23,150 CFU/sample, 
followed by the call bell/TV remote, and the floor.  The toilet flush lever had the lowest 
CFU count pre-decontamination with an average of 1,114 CFU/sample.  The percent 
reduction of facultative bacteria at each location was calculated between the average 
CFU/sample pre- and post-decontamination (Table 2).  The percent reduction of the 
bathroom doorknob and toilet flush handle pre- and post-decontamination was 100%.  
The percent reduction between the remaining samples ranged between 83% and 97%.  
Two samples (4F and 9E) had a 100% reduction rate of CFU in the class Clostridia post-
decontamination. 
Table 1. Surface sampling design for patient rooms 
Pre decontamination: 
Letter designation: Location: 
Total 
samples: 
A Bed rail 9 
B Call bell/TV remote 10 
C Telephone 9 
D Bathroom doorknob 9 
E Toilet flush lever 8 
F Floor 10 
G Bed side table 10 
Total pre-decontamination samples: 65 
Post decontamination: 
H Bed rail 7 
I Call bell/TV remote 10 
J Telephone 9 
K Bathroom doorknob 9 
L Toilet flush lever 8 
M Floor 10 
N Bed side table 10 
Total post-decontamination samples: 63 
Total samples: 128 
33 
 
 
Figure 3.  Mean colony forming units (CFU ± 1 standard error) from surface samples pre- 
and post-decontamination in patient rooms 
0.0
1.0
2.0
3.0
4.0
5.0
6.0
Bed rail Call bell/TV
remote
Telephone Bathroom
doorknob
Toilet flush
lever
Floor Bed side
table
M
e
an
 C
FU
/s
am
p
le
 (
Lo
g 1
0)
 
Sample location 
Pre-decon
Post-decon
Table 2. The percent reduction of facultative bacteria (average CFU/sample ± 1 S.E.) 
pre- and post-decontamination 
Location: Pre-decontamination: Post-decontamination: 
Percent 
reduction: 
Bed rail 2160 (± 898) 347 (± 347)  83.9% 
Call bell/TV 
remote 7254 (± 5727) 324 (± 295) 95.5% 
Telephone 1770 (± 1033) 60 (± 40) 96.6% 
Bathroom 
doorknob 2050 (± 1261) < LDL 100.0% 
Toilet flush lever 1114 (± 961) < LDL 100.0% 
Floor 4680 (± 1678) 240 (± 147) 94.9% 
Bed side table 23150 (± 11333) 1660 (±1594) 92.8% 
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The three facilities utilized different decontamination methods post-patient 
discharge, and the percent reduction of facultative bacteria for each method was 
determined (Table 3).  Decontamination by UV light had a 96.3% reduction in the 
concentration of viable bacteria per sample.  The use of Dispatch® after terminal 
cleaning had a 95.8% reduction, while the use of Dispatch® following a timed terminal 
cleaning of 45 minutes had a 92.9% reduction in CFU/sample.  
 
No culturable C. difficile were detected.  Therefore, culturable facultative 
bacterial concentrations were compared.  The Shapiro Wilks W test was performed to test 
for normality of the distribution.  The results showed a distribution that is not normal at 
the α = 0.05 level (p = 0.000).  Therefore, the non-parametric Wilcoxon Rank Sum test 
statistic was performed to compare the prevalence of CFU/sample in pre-decontamination 
samples and post-decontamination samples using SPSS version 22.  The results showed a 
significant difference at the α = 0.05 level between the number of CFU/sample in pre-
decontamination samples and post-decontamination samples (Z = -5.852, p = 0.000).  
The Wilcoxon Rank Sum test was also performed for each decontamination method.  
Decontamination by UV light showed a significant difference between pre- and post-
decontamination samples (Z = -2.036, p = 0.042).  One facility required 45 minute timed 
Table 3. Decontamination method and average CFU/sample (± 1 S.E.) pre- and post-
decontamination 
Decontamination 
Method: 
Pre-
decontamination: 
Post-
decontamination: 
Percent 
Reduction: 
UV Light (n=28) 2239 (± 1161) 84 (± 48) 96.3% 
Dispatch & Time (n=66) 8289 (± 3760) 593 (± 487) 92.9% 
Dispatch (n=34) 6650 (± 3201) 279 (± 202) 95.8% 
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cleaning with Dispatch® (Z = -3.791, p = 0.000), while the other facility did not use 
timed cleaning (Z = -2.803, p = 0.005).  Both facilities that utilized Dispatch® also had a 
significant difference between pre- and post-decontamination samples.   
PCR Assay 
 Of the 128 samples tested using PCR analysis, five samples were positive for the 
Clostridium difficile 16S rRNA gene sequence (3.9%) (Table 4).  The detection limit was 
estimated to be 90 DNA template copies per sample.  Each sample was initially analyzed 
using an undiluted concentration with an internal positive control (IPC) to test for 
inhibition.  Two undiluted samples of the 128 samples were positive.  Eighty-three of the 
samples exhibited either partial or complete inhibition and necessitated a 10
-1
 dilution to 
resolve inhibition.  Inhibition was determined by a three CT increase in the IPC detector.  
Inhibition resolved at a 10
-1
 dilution for all samples.  After the 10
-1
 dilutions were 
analyzed, three additional samples were positive.  In total, five samples were PCR 
positive.  From the five positive samples, three (4G, 11A, and 11F) were from pre-
decontamination samples and two (6I and 6M) were from post-decontamination samples.  
Rooms with post-decontamination positive samples were negative pre-decontamination.  
Samples were considered positive if the CT value was less than 40.  The five PCR 
positive samples were not culture positive for C. difficile. 
 A standard curve was constructed from known C. difficile DNA concentrations 
versus CT values.  The equation of the line (y = -0.2656x + 9.9617) was then used to 
determine the number of cells in the reaction, and the estimated number of cells per 
sample was calculated. 
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Table 4. The average Ct values for the presence of the Clostridium difficile 16S rRNA  
gene sequence 
Sample Mean Ct Value (± 1 S.E.; n=4) Estimated cells/sample 
4G 38.15 (± 0.56) 150 
6I 37.31 (±0.32) 246 
6M (1:10) 38.89 (± 0.32)* 970 
11A (1:10) 37.23 (± 0.25) 2,580 
11F (1:10) 35.33 (± 0.24) 7,940 
*n=2 
   
 
Figure 4. Standard curve of known Clostridium difficile DNA concentrations versus CT 
values (CT = Cycle threshold)  
y = -0.2565x + 9.9617 
R² = 0.9988 
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CHAPTER 5 
DISCUSSION 
Prevalence of Clostridium difficile 
The main objective of this study was to determine the prevalence of Clostiridum 
difficile on environmental surfaces pre- and post-decontamination in patient rooms with a 
confirmed clinical case of CDI.  Culture analysis results showed no culturable C. difficile.  
Therefore, the hypotheses could not be tested.  Other studies have shown a high 
prevalence of C. difficile on the floor and in the near environment (Kaatz, Gitlin, & 
Schaberg, 1988; Mutters et al., 2008; Riggs, Sethi, Zabarsky, Eckstein, Jump, & 
Donskey, 2007).  Widespread environmental contamination has been seen in up to 75% 
of rooms previously occupied by a CDI patient (McFarland, Mulligan, Kwok, & Stam, 
1989; Weber et at., 2010).  The five PCR positive samples obtained in this study did not 
have any culturable C. difficile.  Research has shown that vegetative cells of Clostridium 
difficile are only viable on dry surfaces for 15 minutes (Weber et at., 2010).  Clostridium 
difficile is also considered a fastidious organism in its vegetative state, meaning it will 
only grow under certain conditions, further limiting positive culture analysis results.  The 
DNA detected in the PCR assay in this study could have been obtained from non-viable 
cells or spores after decontamination.   
The two samples with viable counts from the Clostridia family were identified 
using the Biolog system, but were not PCR positive.  This could be due to the fact that 
Ruminococcus torques and Fusobacterium nucleatum are not closely related to 
Clostridium difficile and do not share the same target DNA sequence.  The primers and 
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probe set used for our PCR assay was a species specific targeting a highly conserved 
region of the 16S rRNA from Clostridium difficile (Mutters et al., 2008). 
Prevalence of Facultative Bacteria 
The BioLog system correctly identified the Clostridium difficile positive control 
strain.  However, culture analysis of the samples was inconclusive.  It is possible that the 
BioLog technology was unable to identify Clostridium difficile or it was present in low 
concentrations below the detection limit of the assay.  In a study conducted by Simmon 
and colleagues, it was determined that anaerobic isolates were misidentified at the species 
level 24% of the time and were deemed inconclusive 10% of the time (Simmon, Mirrett, 
Reller, & Petti, 2007).  In this study, the viable organisms present were either facultative 
anaerobes or strictly anaerobic bacteria not related to Clostridium difficile.  Facultative 
bacteria are organisms that are able to grow in conditions with or without oxygen. 
Given the symptoms of a CDI, it is possible that the bacteria cultured were 
coliform bacteria, which is a group of facultative bacteria most commonly found in the 
feces of warm-blooded animals.  Common coliform bacteria include Escherichia coli and 
species from the genera, Citrobacter, Enterobacter, and Klebsiella.  Escherichia coli is a 
well-known coliform bacterium that is part of the normal human flora; however, 
pathogenic strains are known to cause severe gastrointestinal illness.  Another facultative 
bacterium of concern is Staphylococcus aureus, and the causative agent of the HAI 
methicillin-resistant Staphylococcus aureus.  MRSA infections are generally seen on the 
skin and surgical sites, but it can also infect the lungs, urinary tract, and blood stream.  
Anaerobic bacteria of concern in hospital environments include members of the genera 
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Peptostreptococcus and Bacteroides, as well as Clostridium perfringens, which is known 
to cause gas gangrene. 
Facility Differences 
 The three facilities tested used three different decontamination methods.  From 
the ten rooms tested, two used a UV light post-decontamination; eight of the rooms used 
the EPA-registered disinfectant, Dispatch®, which is equivalent to a 1:10 bleach solution.  
From the eight sites utilizing Dispatch®, five of the sites required a 45 minute timed 
cleaning procedure prior to using Dispatch®, while the remaining two sites did not.  
According to the Clorox Company, Dispatch® requires a five minute contact time to kill 
Clostridium difficile spores.  The three methods all proved to be effective in patient room 
decontamination.  However, due to the low sample size for the decontamination methods, 
no conclusions can be made about which decontamination method is more effective. 
Study Limitations 
 There are various limitations to this study.  One limitation is the relatively small 
sample size.  This was due to low CDI rates and long hospital admissions; this limits the 
strength of the conclusions obtained by comparing pre- and post-decontamination data, 
especially between decontamination methods.  The second limitation is the potential for 
sampling bias.  While hospital personnel were trained on sample collection, sampling 
bias could have occurred with different hospital personnel taking the samples.  The third 
limitation to this study is that the PCR analysis does not determine if the DNA detected 
was from viable or non-viable C. difficile cells and endospores.  Culture analysis was 
used to assess the presence of viable C. difficile, but no culturable C. difficile were 
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detected.  It is possible that Clostridium difficile may have been present below the 
detection limit of the assays used.   
Significance 
 This study showed a decontamination percent reduction of facultative bacteria of 
83% to 100% in post-decontamination samples.  The data suggest that each of the 
decontamination methods proved to be effective and patient rooms were not 
contaminated with Clostridium difficile.  PCR analysis was able to detect C. difficile 
DNA on environmental surfaces.  PCR provides fast results and can be used with culture 
analysis of environmental samples to assess the presence of target microorganisms. 
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CHAPTER 6 
CONCLUSIONS AND RECOMMENDATIONS  
Due to the ubiquitous nature of bacteria, hospital acquired infections will continue 
to be a concern in hospital environments.  There are an estimated 1.7 million HAIs each 
year and 99,000 deaths as a result (Weber et al., 2010).  Although the prevalence of CDI 
is decreasing, it is still one of the main HAIs.  The estimated annual direct cost in the 
USA is nearly $3.4 billion dollars for the treatment of CDIs.  The Centers for Disease 
Control and Prevention has designated C. difficile as one of three microorganisms with 
the highest threat level (Drekonja, 2014).  Clostridium difficile infections cause 
approximately 10% to 35% of all cases of antibiotic-associated diarrhea.  Clostridium 
difficile associated diarrhea is the most common nosocomial diarrhea, which results in 
substantial morbidity and mortality, as well as increased healthcare costs (Khan & 
Elzouki, 2014).  
The main objective of this study was to determine the prevalence of Clostridium 
difficile on environmental surfaces pre- and post-decontamination.  One of the main 
modes of CDI transmission is through the contaminated environment; therefore, seven 
high touch surfaces were tested pre- and post-terminal cleaning.  While no C. difficile 
was cultured, decontamination of patient rooms showed a significant difference in the 
amount of bacteria on surfaces before and after terminal cleaning.  The three 
decontamination methods used proved to be comparable in effectiveness.  PCR analysis 
was able to detect C. difficile DNA in five samples (3.9%), the bedside table, bed rail, 
and the floor pre-decontamination, as well as the call bell/TV remote and floor post-
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decontamination.  This study demonstrates the sensitivity of PCR for enhanced detection 
of microorganisms.   
Reducing the rate of Clostridium difficile infections is dependent on a number of 
factors, including the proper use of antibiotics, environmental decontamination, early 
detection, and proper hand-hygiene.  Four environmental decontamination methods that 
could potentially reduce the rate of CDIs are: 1) improved terminal cleaning, 2) daily 
decontamination of high touch surfaces in isolation rooms, 3) decontamination of 
portable equipment, and 4) improved decontamination of all rooms in cases of 
asymptomatic carriers (Donskey, 2013).  The CDC recommends the use of a 1:10 
dilution of sodium hypochlorite as a disinfectant due to its sporicidal effects.  The 
decontamination methods used in this study conform to the CDC recommendations.  The 
results of this study suggest that the three decontamination methods used are effective at 
reducing surface contamination. 
Early detection is the first step in preventing CDI transmission in hospitals.  The 
Hospital Infection Control Practice Advisory Panel of the Centers for Disease Control 
and Prevention recommends that suspected CDI cases be placed in contact precaution 
isolation until a patient is asymptomatic for 48 to 72 hours (Walters & Zuckerbraun, 
2014; Weber et al., 2010).  Environmental contamination plays an important role in the 
transmission of various HAIs.  Therefore, improved compliance with infection control 
can insure the delivery of the safest health care possible. 
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Appendix A 
IRB Exclusion Form 
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Appendix B 
Environmental Investigation Data Sheet 
UNIVERSITY OF NEVADA, LAS VEGAS 
EMERGING DISEASES LABORATORY, SCHOOL OF COMMUNITY HEALTH SCIENCES 
ENVIRONMENTAL INVESTIGATION DATA SHEET 
 
Facility Name:  __________________  Site Number: ____________ 
 
Sample Collector: ________________  Decontamination Date: ____________ 
 
 
 
 
Pre-
Decontamination 
Site 
number 
Sample 
ID 
Sample Location/Description 
 A bed rail (swab) 
B call bell/television remote control (swab) 
C telephone (swab) 
D bathroom doorknobs (inside and outside) (swab) 
E toilet flush lever (swab) 
F floor (sponge) 
G bed side table (sponge) 
Post-
decontamination 
 H bed rail (swab) 
I call bell/television remote control (swab) 
J telephone (swab) 
K bathroom doorknobs (inside and outside) (swab) 
L toilet flush lever (swab) 
M floor (sponge) 
N bed side table (sponge) 
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Instructions: 
1. Enter information on data sheet 
2. Wearing cleaning gloves, aseptically remove sterile swab, open transport tube, 
and inset swab in transport tube; squeeze tube to express transport buffer from the 
sponge and moisten the swab in the buffer 
3. Remove moistened swab, close transport tube and perform surface sampling with 
swab.  Applying light pressure, swab the surface in an overlapping side-to-side 
pattern over an area of approximately 2 in. by 2 in.  Rotate the swab 180º and 
sample the same area from another (i.e., perpendicular) orientation 
4. Open transport tube, insert exposed swab until it is in contact with the transport 
buffer, close tube 
5. Enter sample information on the sample transport tube label (i.e., site number, 
sample ID, date) 
6. Store transport tube containing swab at 4ºC and contact Theresa Trice (Email: 
theresa.trice@unlv.edu) to arrange sample pickup 
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Appendix C 
Centers for Disease Control and Prevention’s Surface Sampling Procedures for Bacillus 
anthracis spores from smooth, non-porous surfaces 
Macrofoam Swab Procedure 
Swab Materials 
1. Gloves, nitrile  
2. Ruler, disposable, and masking tape 
or 
Sample template, disposable, sample area size 4 in
2
 (26 cm
2
) 
3. Macrofoam swab, sterile, 3/16 inch thick medical-grade polyurethane foam head, 100 
pores per inch, thermally bonded to a polypropylene stick (such as the Sterile Foam 
Tipped Applicators Scored with Thumb Stop [Puritan, Guilford, Maine; catalog number 
25-1607 1PF SC] or equivalent) 
4. General neutralizing buffer that will inactivate halogen disinfectants and quaternary 
ammonium compounds, 10 milliliter (ml), sterile (such as the Neutralizing Buffer [Hardy 
Diagnostics, Santa Maria, California; catalog number K105] or equivalent) 
5. Screw-cap centrifuge tubes, sterile, 15 ml (such as 15 ml High-Clarity Polypropylene 
Conical Centrifuge Tube [Becton Dickinson, Franklin Lakes, New Jersey; catalog 
number 352097] or equivalent) 
6. Sample labels 
or 
Permanent marker 
7. Re-sealable plastic bag, 1-quart or smaller 
8. Re-sealable plastic bag, 1-gallon or larger 
 
Swab Sampling Procedure 
1. Wearing a clean pair of gloves over existing gloves, place the disposable template over 
the area to be sampled and secure it. If the template cannot be used, measure the 
sampling area with a disposable ruler, and delineate the area to be sampled with masking 
tape. 
2. Remove the sterile swab from its package. Grasp the swab near the top of the handle. Do 
not handle below the thumb stop. 
3. If the sterile swab is not pre-moistened, moisten the sterile swab by dipping it in the 10 
ml container of neutralizing buffer solution. Remove any excess liquid by pressing the 
swab head on the inside surface of the neutralizing buffer solution container.  
Note: Once a sterile swab has been moistened, the remaining neutralizing buffer solution 
and container must be discarded. 
4. Swab the surface to be sampled using the moistened sterile swab. Use an overlapping ‘S’ 
pattern to cover the entire surface with horizontal strokes.  
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Note: Depending on the design of the swab, a rolling motion can be used when swabbing 
the surface to maximize swab contact with the surface. 
5. Rotate the swab and swab the same area again using vertical ‘S’-strokes.  
 
6. Rotate the swab once more and swab the same area using diagonal ‘S’-strokes.  
 
7. Place the head of the swab directly into a sterile screw-capped centrifuge tube. Break off 
the head of the swab by bending the handle. The end of the swab handle, touched by the 
collector, should not touch the inside of the tube. Securely tighten the screw-cap and 
label the tube (e.g., unique sample identifier, sample location, initials of collectors and 
date and time sample was collected). Collection tubes and re-sealable bags may be pre-
labeled to assist with sampling efficiency. 
8. Place the sample container in a re-sealable 1-quart plastic bag. Securely seal and label the 
bag (e.g., sample location, date and time sample was collected, and name of individual 
collecting the sample).  
Note: Remove excessive air from the re-sealable plastic bags to increase the number of 
samples that can be shipped in one container. 
9. Dispose of the template, if used. 
10. Remove outer gloves and discard. Clean gloves must be worn for each new sample. 
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Cellulose Sponge Procedure 
Cellulose Sponge Materials  
1. Gloves, nitrile  
2. Ruler, disposable, and masking tape 
or 
Sample template, disposable, sample area size 100 in
2
 (645 cm
2
) 
3. Sponge, sterile, pre-moistened with 10 ml neutralizing buffer solution, 1.5 by 3 inches 
cellulose sponge folded over a handle (such as the 3M™ Sponge-Stick [3M, St. Paul, 
Minnesota; catalog number SSL-10NB] or equivalent)
1
 
or 
Sponge, sterile, dry, 1.5 by 3 inches cellulose sponge folded over a handle (such as the 
3M™ Sponge-Stick [3M, St. Paul, Minnesota; catalog number SSL-100] or equivalent) 
and 
General neutralizing buffer that will inactivate halogen disinfectants and quaternary 
ammonium compounds, sterile, 10 ml (such as the Neutralizing Buffer [Hardy 
Diagnostics, Santa Maria, California; catalog number K105] or equivalent) 
4. Screw-cap specimen container, sterile, individually wrapped 4 ounce (such as General 
Purpose Specimen Container [Kendall Healthcare, Mansfield, Massachusetts; catalog 
number 8889-207026] or equivalent) 
5. Sample labels 
or 
Permanent marker 
6. Re-sealable plastic bag, 1-quart or smaller 
7. Re-sealable plastic bag, 1-gallon or larger 
 
Cellulose Sponge Sampling Procedure 
1. Wearing a clean pair of gloves over existing gloves, place the disposable template over 
the area to be sampled and secure it. If a template cannot be used, measure the sampling 
area with a disposable ruler, and delineate the area to be sampled with masking tape. The 
surface area sampled should be less than or equal to 100 in
2
 (645 cm
2
). 
2. Remove the sterile sponge from its package. Grasp the sponge near the top of the handle. 
Do not handle below the thumb stop. 
3. If the sterile sponge is not pre-moistened, moisten the sponge by pouring the 10 ml 
container of neutralizing buffer solution over the dry sponge.  
Note: The moistened sponge should not be dripping neutralizing buffer solution. 
Note: Any unused neutralizing buffer solution must be discarded. 
4. Wipe the surface to be sampled using the moistened sterile sponge by laying the widest 
part of the sponge on the surface, leaving the leading edge slightly lifted. Apply gentle 
but firm pressure and use an overlapping ‘S’ pattern to cover the entire surface with 
horizontal strokes.  
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5. Turn the sponge over and wipe the same area again using vertical ‘S’-strokes.  
 
6. Use the edges of the sponge (narrow sides) to wipe the same area using diagonal ‘S’-
strokes.  
 
7. Use the tip of the sponge to wipe the perimeter of the sampling area.  
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8. Place the head of the sponge directly into a sterile specimen container. Break off the head 
of the sponge by bending the handle. The end of the sponge handle, touched by the 
collector, should not touch the inside of the specimen container. Securely seal and label 
the container (e.g., unique sample identifier, sample location, initials of collector and date 
and time sample was collected). 
9. Place the sample container in a re-sealable 1-quart plastic bag. Securely seal and label the 
bag (e.g., sample location, date and time sample was collected, and name of individual 
collecting the sample). Specimen containers and re-sealable bags may be pre-labeled to 
assist with sampling efficiency.  
Note: Remove excessive air from the re-sealable plastic bags to increase the number of 
samples that can be shipped in one container. 
10. Dispose of the template, if used. 
Remove outer gloves and discard. Clean gloves should be worn for each new sample 
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Appendix D 
Culture Analysis Data 
PRE 
Site/ 
location: 
Volume: Dilution: CFU: CFU/
ml: 
CFU/ 
sample: 
Log CFU/ 
Sample: 
Organism: 
4A .1  ml 1:30 17 510 4,590 3.662 Facultative 
bacteria 
4B .1  ml 1:30 0 0 0 0.000  
4C .1  ml 1:30 1 30 270 2.431 Facultative 
bacteria 
4D .1  ml 1:30 1 30 270 2.431 Facultative 
bacteria 
4E .1  ml 1:30 1 30 270 2.431 Facultative 
bacteria 
4F .1  ml 1:30 5 150 1,500 3.176 Facultative 
bacteria 
   35 1,100 11,000 4.041 Ruminococcus 
torques 
4G .1  ml 1:30 3 90 900 2.954 Facultative 
bacteria 
        
5A .1 ml 1:30 1 30 270 2.431 Facultative 
bacteria 
5B .1 ml 1:30 0 0 0 0.000  
5C .1 ml 1:30 0 0 0 0.000  
5D .1 ml 1:30 43 1300 11700 4.068 Facultative 
bacteria 
5E .1 ml 1:30 1 30 270 2.431 Facultative 
bacteria 
5F .1 ml 1:30 1 30 300 2.477 Facultative 
bacteria 
5G .1 ml 1:30 0 0 0 0.000  
        
6A .1  ml 1:30 3 90 810 2.908 Facultative 
bacteria 
6B .1  ml 1:30 215 6,500 58500 4.767 Facultative 
bacteria 
6C .1  ml 1:30 23 690 6210 3.793 Facultative 
bacteria 
6D .1  ml 1:30 10 300 2700 3.431 Facultative 
bacteria 
6E .1  ml 1:30 0 0 0 0.000  
6F .1  ml 1:30 13 390 3900 3.591 Facultative 
bacteria 
6G .1  ml 1:30 30 900 9000 3.954 Facultative 
bacteria 
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PRE 
Site/ 
location: 
Volume: Dilution: CFU: CFU/
ml: 
CFU/ 
sample: 
Log CFU/ 
Sample: 
Organism: 
7A nd x x x x x  
7B .1  ml 1:30 3 90 810 2.908 Facultative 
bacteria 
7C .1  ml 1:30 3 90 810 2.908 Facultative 
bacteria 
7D .1  ml 1:30 3 90 810 2.908 Facultative 
bacteria 
7E .1  ml 1:30 1 30 270 2.431 Facultative 
bacteria 
7F .1  ml 1:30 19 570 5700 3.756 Facultative 
bacteria 
7G .1  ml 1:30 107 3,200 32000 4.505 Facultative 
bacteria 
        
8A .1 ml 1:30 2 60 540 2.732 Facultative 
bacteria 
8B .1 ml 1:30 2 60 540 2.732 Facultative 
bacteria 
8C .1 ml 1:30 1 30 270 2.431 Facultative 
bacteria 
8D .1 ml 1:30 0 0 0 0.000  
8E nd x x x x x  
8F .1 ml 1:30 50 1,500 15,000 4.176 Facultative 
bacteria 
8G .1 ml 1:30 300 9,000 90,000 4.954 Facultative 
bacteria 
        
9A .1 ml 1:30 4 120 1080 3.033 Facultative 
bacteria 
9B .1 ml 1:30 0 0 0 0.000  
9C .1 ml 1:30 1 30 270 2.431 Facultative 
bacteria 
9D .1 ml 1:30 0 0 0 0.000  
9E .1 ml 1:30 29 870 7830 3.894 Fusobacterium 
nucleatum 
9F .1 ml 1:30 24 720 7200 3.857 Facultative 
bacteria 
9G .1 ml 1:30 291 8,700 87000 4.940 Facultative 
bacteria 
        
10A .1 ml 1:30 18 540 4860 3.687 Facultative 
bacteria 
10B .1 ml 1:30 1 30 270 2.431 Facultative 
bacteria 
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PRE 
Site/ 
location: 
Volume: Dilution: CFU: CFU/
ml: 
CFU/ 
sample: 
Log CFU/ 
Sample: 
Organism: 
10C .1 ml 1:30 0 0 0 0.000  
10D .1 ml 1:30 0 0 0 0.000  
10E .1 ml 1:30 0 0 0 0.000  
10F .1 ml 1:30 4 120 1200 3.079 Facultative 
bacteria 
10G .1 ml 1:30 2 60 600 2.778 Facultative 
bacteria 
        
11A .1 ml 1:30 0 0 0 0.000  
11B .1 ml 1:30 20 600 5400 3.732 Facultative 
bacteria 
11C .1 ml 1:30 30 900 8100 3.908 Facultative 
bacteria 
11D .1 ml 1:30 10 300 2700 3.431 Facultative 
bacteria 
11E .1 ml 1:30 1 30 270 2.431 Facultative 
bacteria 
11F .1 ml 1:30 0 0 0 0.000  
11G .1 ml 1:30 0 0 0 0.000  
        
13A .1 ml 1:30 0 0 0 0  
13B .1 ml 1:30 11 330 2970 3.473 Facultative 
bacteria 
13C nd x x x x x  
13D nd x x x x x  
13E nd x x x x x  
13F .1 ml 1:30 0 0 0 0  
13G .1 ml 1:30 0 0 0 0  
        
14A .1 ml 1:30 27 810 7290 3.863 Facultative 
bacteria 
14B .1 ml 1:30 15 450 4050 3.607 Facultative 
bacteria 
14C .1 ml 1:30 0 0 0 0.000  
14D .1 ml 1:30 1 30 270 2.431 Facultative 
bacteria 
14E .1 ml 1:30 0 0 0 0.000  
14F .1 ml 1:30 41 1200 12000 4.079 Facultative 
bacteria 
14G .1 ml 1:30 41 1200 12000 4.079 Facultative 
bacteria 
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POST 
Site/ 
location: 
Volume: Dilution: CFU: CFU/
ml: 
CFU/ 
sample: 
Log CFU/ 
Sample: 
Organism: 
4H .1  ml 1:30 0 0 0 0.000  
4I .1  ml 1:30 0 0 0 0.000  
4J .1  ml 1:30 0 0 0 0.000  
4K .1  ml 1:30 0 0 0 0.000  
4L .1  ml 1:30 0 0 0 0.000  
4M .1  ml 1:30 0 0 0 0.000  
    0 0 0.000  
4N .1 mL 1:30 0 0 0 0.000  
        
5H .1 ml 1:30 0 0 0 0.000  
5I .1 ml 1:30 0 0 0 0.000  
5J .1 ml 1:30 1 30 270 2.431 Facultative 
bacteria 
5K .1 ml 1:30 0 0 0 0.000  
5L .1 ml 1:30 0 0 0 0.000  
5M .1 ml 1:30 1 30 300 2.477 Facultative 
bacteria 
5N .1 ml 1:30 2 60 600 2.778 Facultative 
bacteria 
        
6H nd x x x x x  
6I .1  ml 1:30 0 0 0 0.000  
6J .1  ml 1:30 0 0 0 0.000  
6K .1  ml 1:30 0 0 0 0.000  
6L .1  ml 1:30 0 0 0 0.000  
6M .1  ml 1:30 0 0 0 0.000  
6N .1  ml 1:30 0 0 0 0.000  
        
7H nd x x x x x  
7I .1  ml 1:30 1 30 270 2.431 Facultative 
bacteria 
7J .1  ml 1:30 0 0 0 0.000  
7K .1  ml 1:30 0 0 0 0.000  
7L .1  ml 1:30 0 0 0 0.000  
7M .1  ml 1:30 1 30 300 2.477 Facultative 
bacteria 
7N .1  ml 1:30 0 0 0 0.000  
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POST 
Site/ 
location: 
Volume: Dilution: CFU: CFU/
ml: 
CFU/ 
sample: 
Log CFU/ 
Sample: 
Organism: 
8H .1 ml 1:30 0 0 0 0.000  
8I .1 ml 1:30 0 0 0 0.000  
8J .1 ml 1:30 0 0 0 0.000  
8K .1 ml 1:30 0 0 0 0.000  
8L nd x  x x x  
8M .1 ml 1:30 0 0 0 0.000  
8N .1 ml 1:30 0 0 0 0.000  
        
9H .1 ml 1:30 0 0 0 0.000  
9I .1 ml 1:30 0 0 0 0.000  
9J .1 ml 1:30 0 0 0 0.000  
9K .1 ml 1:30 0 0 0 0.000  
9L .1 ml 1:30 0 0 0 0.000  
9M .1 ml 1:30 1 30 300 2.477 Facultative 
bacteria 
9N .1 ml 1:30 0 0 0 0.000  
        
10H .1 ml 1:30 9 270 2430 3.386 Facultative 
bacteria 
10I .1 ml 1:30 0 0 0 0.000  
10J .1 ml 1:30 1 30 270 2.431 Facultative 
bacteria 
10K .1 ml 1:30 0 0 0 0.000  
10L .1 ml 1:30 0 0 0 0.000  
10M .1 ml 1:30 0 0 0 0.000  
10N .1 ml 1:30 0 0 0 0.000  
        
11H .1 ml 1:30 0 0 0 0.000  
11I .1 ml 1:30 0 0 0 0.000  
11J .1 ml 1:30 0 0 0 0.000  
11K .1 ml 1:30 0 0 0 0.000  
11L .1 ml 1:30 0 0 0 0.000  
11M .1 ml 1:30 0 0 0 0.000  
11N .1 ml 1:30 52 1,600 16000 4.204 Facultative 
bacteria 
        
13H .1 ml 1:30 0 0 0 0.000  
13I .1 ml 1:30 0 0 0 0.000  
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POST 
Site/ 
location: 
Volume: Dilution: CFU: CFU/
ml: 
CFU/ 
sample: 
Log CFU/ 
Sample: 
Organism: 
13J nd 1:30 x x x x  
13K nd 1:30 x x x x  
13L nd 1:30 x x x x  
13M .1 ml 1:30 0 0 0 0.000  
13N .1 ml 1:30 0 0 0 0.000  
        
14H nd x x x x x  
14I .1 ml 1:30 11 330 2970 3.473 Facultative 
bacteria 
14J .1 ml 1:30 0 0 0 0.000  
14K .1 ml 1:30 0 0 0 0.000  
14L .1 ml 1:30 0 0 0 0.000  
14M .1 ml 1:30 5 150 1500 3.176 Facultative 
bacteria 
14N .1 ml 1:30 0 0 0 0.000  
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Appendix E 
Internal positive control (IPC) PCR Data  
(NAC = No amplification control, NTC = No template control, 10
-5
 = positive control)  
Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
4A 4 IPC 29.18 29.22 
4A 4 IPC 29.25  
5A 5 IPC 28.76 29.76 
5A 5 IPC 30.76  
6A 6 IPC 28.87 28.92 
6A 6 IPC 28.97  
8A 8 IPC Undetermined  
8A 8 IPC Undetermined  
8A (1:10) 8 IPC 29.02 29.21 
8A (1:10) 8 IPC 29.40  
9A 9 IPC Undetermined  
9A 9 IPC Undetermined  
9A (1:10) 9 IPC 29.34 29.41 
9A (1:10) 9 IPC 29.47  
10A 10 IPC Undetermined  
10A 10 IPC Undetermined  
10A (1:10) 10 IPC 28.77 28.75 
10A (1:10) 10 IPC 28.73  
11A 11 IPC Undetermined  
11A 11 IPC Undetermined  
11A (1:10) 11 IPC 29.09 29.02 
11A (1:10) 11 IPC 28.94  
11A (1:10) 11 IPC 28.97 29.01 
11A (1:10) 11 IPC 29.05  
13A 13 IPC 29.26 29.33 
13A 13 IPC 29.41  
14A 14 IPC Undetermined  
14A 14 IPC Undetermined  
14A (1:10) 14 IPC 28.50 28.40 
14A (1:10) 14 IPC 28.31  
4B 4 IPC 39.61 39.55 
4B 4 IPC 39.49  
4B (1:10) 4 IPC 28.89 28.86 
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Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
4B (1:10) 4 IPC 28.83  
5B 5 IPC 29.32 29.40 
5B 5 IPC 29.47  
6B 6 IPC 28.91 28.90 
6B 6 IPC 28.89  
7B 7 IPC 34.11 33.27 
7B 7 IPC 32.42  
7B (1:10) 7 IPC 29.25 29.20 
7B (1:10) 7 IPC 29.15  
8B 8 IPC Undetermined  
8B 8 IPC Undetermined  
8B (1:10) 8 IPC 29.11 29.24 
8B (1:10) 8 IPC 29.37  
9B 9 IPC Undetermined  
9B 9 IPC Undetermined  
9B (1:10) 9 IPC 29.25 29.35 
9B (1:10) 9 IPC 29.44  
10B 10 IPC Undetermined  
10B 10 IPC Undetermined  
10B (1:10) 10 IPC 29.32 29.08 
10B (1:10) 10 IPC 28.83  
11B 11 IPC Undetermined  
11B 11 IPC Undetermined  
11B (1:10) 11 IPC 29.04 28.95 
11B (1:10) 11 IPC 28.87  
13B 13 IPC 29.17 29.13 
13B 13 IPC 29.08  
14B 14 IPC Undetermined  
14B 14 IPC Undetermined  
14B (1:10) 14 IPC 28.58 28.71 
14B (1:10) 14 IPC 28.84  
4C 4 IPC 29.67 29.66 
4C 4 IPC 29.65  
5C 5 IPC 30.28 30.17 
5C 5 IPC 30.05  
6C 6 IPC 28.82 28.90 
6C 6 IPC 28.98  
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Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
7C 7 IPC 31.98 31.61 
7C 7 IPC 31.24  
7C (1:10) 7 IPC 28.96 29.01 
7C (1:10) 7 IPC 29.07  
8C 8 IPC Undetermined  
8C 8 IPC Undetermined  
8C (1:10) 8 IPC 29.25 29.09 
8C (1:10) 8 IPC 28.92  
9C 9 IPC Undetermined  
9C 9 IPC Undetermined  
9C (1:10) 9 IPC 29.37 29.08 
9C (1:10) 9 IPC 28.79  
10C 10 IPC Undetermined  
10C 10 IPC Undetermined  
10C (1:10) 10 IPC 29.03 29.14 
10C (1:10) 10 IPC 29.25  
11C 11 IPC Undetermined  
11C 11 IPC Undetermined  
11C (1:10) 11 IPC 29.00 28.84 
11C (1:10) 11 IPC 28.68  
14C 14 IPC 34.67 34.35 
14C 14 IPC 34.03  
14C (1:10) 14 IPC 28.31 28.28 
14C (1:10) 14 IPC 28.25  
4D 4 IPC 30.98 31.53 
4D 4 IPC 32.08  
4D (1:10) 4 IPC 28.94 28.86 
4D (1:10) 4 IPC 28.77  
5D 5 IPC 30.28 30.50 
5D 5 IPC 30.73  
6D 6 IPC 28.68 28.67 
6D 6 IPC 28.65  
7D 7 IPC 31.98 31.62 
7D 7 IPC 31.27  
7D (1:10) 7 IPC 28.87 28.84 
7D (1:10) 7 IPC 28.82  
8D 8 IPC Undetermined  
60 
 
Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
8D 8 IPC Undetermined  
8D (1:10) 8 IPC 28.83 28.62 
8D (1:10) 8 IPC 28.41  
9D 9 IPC 34.19 34.21 
9D 9 IPC 34.23  
9D (1:10) 9 IPC 28.88 29.18 
9D (1:10) 9 IPC 29.47  
10D 10 IPC Undetermined  
10D 10 IPC Undetermined  
10D (1:10) 10 IPC 28.96 28.85 
10D (1:10) 10 IPC 28.74  
11D 11 IPC 30.85 30.69 
11D 11 IPC 30.54  
14D 14 IPC Undetermined  
14D 14 IPC Undetermined  
14D (1:10) 14 IPC 28.53 28.43 
14D (1:10) 14 IPC 28.33  
4E 4 IPC 30.81 30.56 
4E 4 IPC 30.31  
5E 5 IPC 30.63 30.37 
5E 5 IPC 30.10  
6E 6 IPC 28.90 29.11 
6E 6 IPC 29.32  
7E 7 IPC 30.42 30.60 
7E 7 IPC 30.78  
9E 9 IPC 30.58 30.30 
9E 9 IPC 30.01  
10E 10 IPC Undetermined  
10E 10 IPC Undetermined  
10E (1:10) 10 IPC 28.90 28.87 
10E (1:10) 10 IPC 28.84  
11E 11 IPC 32.62 32.51 
11E 11 IPC 32.39  
11E (1:10) 11 IPC 28.68 28.70 
11E (1:10) 11 IPC 28.72  
14E 14 IPC Undetermined  
14E 14 IPC Undetermined  
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Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
14E (1:10) 14 IPC 28.51 28.30 
14E (1:10) 14 IPC 28.09  
4F 4 IPC 30.05 30.04 
4F 4 IPC 30.03  
4F 4 IPC 30.04 30.14 
4F 4 IPC 30.23  
5F 5 IPC 36.52 36.78 
5F 5 IPC 37.04  
5F (1:10) 5 IPC 29.12 28.87 
5F (1:10) 5 IPC 28.62  
6F 6 IPC Undetermined  
6F 6 IPC Undetermined  
6F (1:10) 6 IPC 28.78 28.71 
6F (1:10) 6 IPC 28.63  
7F 7 IPC Undetermined  
7F 7 IPC Undetermined  
7F (1:10) 7 IPC 29.30 29.27 
7F (1:10) 7 IPC 29.25  
8F 8 IPC 32.88 32.84 
8F 8 IPC 32.79  
8F (1:10) 8 IPC 28.27 28.39 
8F (1:10) 8 IPC 28.51  
9F 9 IPC 29.60 29.58 
9F 9 IPC 29.56  
10F 10 IPC Undetermined  
10F 10 IPC Undetermined  
10F (1:10) 10 IPC 28.66 28.45 
10F (1:10) 10 IPC 28.25  
11F 11 IPC Undetermined  
11F 11 IPC Undetermined  
11F (1:10) 11 IPC 29.08 29.18 
11F (1:10) 11 IPC 29.28  
11F (1:10) 11 IPC 29.46 29.28 
11F (1:10) 11 IPC 29.09  
13F 13 IPC 30.43 30.27 
13F 13 IPC 30.11  
14F 14 IPC Undetermined  
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Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
14F 14 IPC Undetermined  
14F (1:10) 14 IPC 28.26 28.26 
14F (1:10) 14 IPC 28.26  
4G 4 IPC 29.49 29.60 
4G 4 IPC 29.72  
4G 4 IPC 29.09 28.92 
4G 4 IPC 28.75  
4G 4 IPC 29.71 29.61 
4G 4 IPC 29.52  
5G 5 IPC 30.46 30.60 
5G 5 IPC 30.75  
6G 6 IPC 28.63 28.64 
6G 6 IPC 28.65  
7G 7 IPC Undetermined  
7G 7 IPC Undetermined  
7G (1:10) 7 IPC Undetermined  
7G (1:10) 7 IPC 30.34  
7G (1:10) 7 IPC 29.91 29.42 
7G (1:10) 7 IPC 28.93  
8G 8 IPC Undetermined  
8G 8 IPC Undetermined  
8G (1:10) 8 IPC 28.72 28.74 
8G (1:10) 8 IPC 28.77  
9G 9 IPC Undetermined  
9G 9 IPC Undetermined  
9G (1:10) 9 IPC 30.16 29.91 
9G (1:10) 9 IPC 29.66  
10G 10 IPC Undetermined  
10G 10 IPC Undetermined  
10G (1:10) 10 IPC 28.43 28.48 
10G (1:10) 10 IPC 28.52  
11G 11 IPC 35.69 35.19 
11G 11 IPC 34.70  
11G (1:10) 11 IPC 28.67 28.62 
11G (1:10) 11 IPC 28.56  
13G 13 IPC 29.40 29.26 
13G 13 IPC 29.11  
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Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
14G 14 IPC 35.64 35.31 
14G 14 IPC 34.98  
14G (1:10) 14 IPC 26.81  
14G (1:10) 14 IPC Undetermined  
14G (1:10) 14 IPC 28.69 28.49 
14G (1:10) 14 IPC 28.28  
4H 4 IPC 31.15 31.15 
4H 4 IPC 31.15  
4H (1:10) 4 IPC 29.09 28.92 
4H (1:10) 4 IPC 28.75  
5H 5 IPC 32.56 32.27 
5H 5 IPC 31.99  
5H (1:10) 5 IPC 28.61 28.52 
5H (1:10) 5 IPC 28.42  
8H 8 IPC 31.24 31.02 
8H 8 IPC 30.81  
8H (1:10) 8 IPC 28.36 28.35 
8H (1:10) 8 IPC 28.35  
9H 9 IPC 36.46 36.24 
9H 9 IPC 36.03  
9H (1:10) 9 IPC 29.34 29.26 
9H (1:10) 9 IPC 29.19  
10H 10 IPC 34.22 33.68 
10H 10 IPC 33.13  
10H (1:10) 10 IPC 28.33 28.36 
10H (1:10) 10 IPC 28.39  
11H 11 IPC 30.78 31.24 
11H 11 IPC 31.69  
11H (1:10) 11 IPC 28.71 28.56 
11H (1:10) 11 IPC 28.41  
13H 13 IPC 29.94 29.80 
13H 13 IPC 29.66  
4I 4 IPC 31.59 31.42 
4I 4 IPC 31.26  
4I (1:10) 4 IPC 28.73 28.83 
4I (1:10) 4 IPC 28.93  
5I 5 IPC 30.80 30.61 
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Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
5I 5 IPC 30.42  
6I 6 IPC 29.10 29.32 
6I 6 IPC 29.53  
6I 6 IPC 29.66 29.40 
6I 6 IPC 29.14  
6I 6 IPC 29.95 29.81 
6I 6 IPC 29.68  
7I 7 IPC Undetermined  
7I 7 IPC 39.71  
7I (1:10) 7 IPC 29.02 29.02 
7I (1:10) 7 IPC 29.03  
8I 8 IPC Undetermined  
8I 8 IPC Undetermined  
8I (1:10) 8 IPC 29.13 29.35 
8I (1:10) 8 IPC 29.56  
9I 9 IPC 30.42 30.32 
9I 9 IPC 30.21  
10I 10 IPC 36.16 35.33 
10I 10 IPC 34.50  
10I (1:10) 10 IPC 28.68 28.54 
10I (1:10) 10 IPC 28.40  
11I 11 IPC 30.59 30.37 
11I 11 IPC 30.15  
13I 13 IPC 30.97 30.27 
13I 13 IPC 29.58  
14I 14 IPC 34.38 33.87 
14I 14 IPC 33.37  
14I (1:10) 14 IPC 28.32 28.14 
14I (1:10) 14 IPC 27.95  
4J 4 IPC 31.15 31.14 
4J 4 IPC 31.14  
4J (1:10) 4 IPC 28.88 28.64 
4J (1:10) 4 IPC 28.40  
5J 5 IPC 29.26 29.26 
5J 5 IPC 29.27  
6J 6 IPC 28.98 28.82 
6J 6 IPC 28.66  
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Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
7J 7 IPC 32.59 32.29 
7J 7 IPC 31.99  
7J (1:10) 7 IPC 28.95 28.97 
7J (1:10) 7 IPC 29.00  
8J 8 IPC Undetermined  
8J 8 IPC Undetermined  
8J (1:10) 8 IPC 28.94 28.85 
8J (1:10) 8 IPC 28.77  
9J 9 IPC Undetermined  
9J 9 IPC Undetermined  
9J (1:10) 9 IPC 29.97 29.87 
9J (1:10) 9 IPC 29.77  
10J 10 IPC 31.30 31.44 
10J 10 IPC 31.58  
10J (1:10) 10 IPC 28.43 28.43 
10J (1:10) 10 IPC 28.43  
11J 11 IPC 30.50 30.48 
11J 11 IPC 30.47  
14J 14 IPC Undetermined  
14J 14 IPC Undetermined  
14J (1:10) 14 IPC 27.69 27.25 
14J (1:10) 14 IPC 26.81  
4K 4 IPC 31.05 30.90 
4K 4 IPC 30.76  
4K (1:10) 4 IPC 28.92 28.85 
4K (1:10) 4 IPC 28.78  
5K 5 IPC 32.55 32.07 
5K 5 IPC 31.59  
5K (1:10) 5 IPC 28.54 28.55 
5K (1:10) 5 IPC 28.56  
6K 6 IPC 28.63 28.52 
6K 6 IPC 28.42  
7K 7 IPC 34.44 33.95 
7K 7 IPC 33.46  
7K (1:10) 7 IPC 30.2 30.10 
7K (1:10) 7 IPC 30.0  
8K 8 IPC 30.00 30.23 
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Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
8K 8 IPC 30.45  
9K 9 IPC 29.71 29.39 
9K 9 IPC 29.08  
10K 10 IPC Undetermined  
10K 10 IPC Undetermined  
10K (1:10) 10 IPC 28.33 28.27 
10K (1:10) 10 IPC 28.20  
11K 11 IPC 29.68 29.89 
11K 11 IPC 30.11  
14K 14 IPC 36.35 36.36 
14K 14 IPC 36.37  
14K (1:10) 14 IPC 28.33 28.30 
14K (1:10) 14 IPC 28.26  
4L 4 IPC 30.65 30.64 
4L 4 IPC 30.64  
5L 5 IPC 31.55 31.49 
5L 5 IPC 31.42  
5L (1:10) 5 IPC 28.64 28.63 
5L (1:10) 5 IPC 28.61  
6L 6 IPC 29.60 29.64 
6L 6 IPC 29.67  
7L 7 IPC 37.68 37.74 
7L 7 IPC 37.80  
7L (1:10) 7 IPC 28.48 28.50 
7L (1:10) 7 IPC 28.51  
9L 9 IPC 30.43 30.21 
9L 9 IPC 29.98  
10L 10 IPC 39.90 39.92 
10L 10 IPC 39.94  
10L (1:10) 10 IPC 28.41 28.50 
10L (1:10) 10 IPC 28.58  
11L 11 IPC Undetermined  
11L 11 IPC Undetermined  
11L (1:10) 11 IPC 28.86 28.79 
11L (1:10) 11 IPC 28.72  
14L 14 IPC 39.71 39.20 
14L 14 IPC 38.69  
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Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
14L (1:10) 14 IPC 28.02 28.11 
14L (1:10) 14 IPC 28.21  
4M 4 IPC 28.91 29.18 
4M 4 IPC 29.45  
4M 4 IPC 29.45 29.39 
4M 4 IPC 29.32  
5M 5 IPC 32.08 31.57 
5M 5 IPC 31.05  
5M (1:10) 5 IPC 28.46 28.33 
5M (1:10) 5 IPC 28.19  
6M 6 IPC 35.61 35.52 
6M 6 IPC 35.44  
6M (1:10) 6 IPC 28.60 28.49 
6M (1:10) 6 IPC 28.38  
6M (1:10) 6 IPC 28.54 28.45 
6M (1:10) 6 IPC 28.37  
7M 7 IPC 31.26 30.85 
7M 7 IPC 30.44  
7M (1:10) 7 IPC 28.37 28.38 
7M (1:10) 7 IPC 28.39  
8M 8 IPC 33.63 33.51 
8M 8 IPC 33.38  
8M (1:10) 8 IPC 28.57 28.38 
8M (1:10) 8 IPC 28.19  
9M 9 IPC Undetermined  
9M 9 IPC Undetermined  
9M (1:10) 9 IPC 30.05 30.08 
9M (1:10) 9 IPC 30.11  
10M 10 IPC Undetermined  
10M 10 IPC Undetermined  
10M 
(1:10) 
10 IPC 28.51 28.78 
10M 
(1:10) 
10 IPC 29.04  
11M 11 IPC 30.43 30.20 
11M 11 IPC 29.97  
13M 13 IPC 30.67 30.65 
13M 13 IPC 30.64  
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Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
14M 14 IPC Undetermined  
14M 14 IPC Undetermined  
14M 
(1:10) 
14 IPC 28.25 28.15 
14M 
(1:10) 
14 IPC 28.05  
4N 4 IPC 31.51 31.37 
4N 4 IPC 31.23  
4N (1:10) 4 IPC 28.44 28.41 
4N (1:10) 4 IPC 28.38  
5N 5 IPC 33.20 32.91 
5N 5 IPC 32.62  
5N (1:10) 5 IPC 28.54 28.55 
5N (1:10) 5 IPC 28.56  
6N 6 IPC 28.38 28.29 
6N 6 IPC 28.20  
7N 7 IPC 34.53 34.74 
7N 7 IPC 34.95  
7N (1:10) 7 IPC 29.01 28.84 
7N (1:10) 7 IPC 28.68  
8N 8 IPC 32.26 32.26 
8N 8 IPC 32.25  
8N (1:10) 8 IPC 28.56 28.58 
8N (1:10) 8 IPC 28.60  
9N 9 IPC 32.23 32.02 
9N 9 IPC 31.82  
9N (1:10) 9 IPC 28.48 28.49 
9N (1:10) 9 IPC 28.51  
10N 10 IPC Undetermined  
10N 10 IPC Undetermined  
10N (1:10) 10 IPC 30.36 29.43 
10N (1:10) 10 IPC 28.51  
11N 11 IPC 24.04 27.70 
11N 11 IPC 31.35  
11N 11 IPC 35.70 33.52 
11N 11 IPC 31.34  
11N (1:10) 11 IPC 28.76 28.61 
11N (1:10) 11 IPC 28.47  
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Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
13N 13 IPC 30.15 30.08 
13N 13 IPC 30.01  
14N 14 IPC 34.05 34.03 
14N 14 IPC 34.01  
14N (1:10) 14 IPC 28.07 28.04 
14N (1:10) 14 IPC 28.02  
10
-5
  IPC 28.25 28.23 
10
-5
  IPC 28.21  
10
-5
  IPC 27.96 28.02 
10
-5
  IPC 28.07  
10
-5
  IPC 28.27 28.28 
10
-5
  IPC 28.28  
10
-5
  IPC 27.91 27.86 
10
-5
  IPC 27.82  
10
-5
  IPC 28.30 28.31 
10
-5
  IPC 28.32  
10
-5
  IPC 28.06 28.19 
10
-5
  IPC 28.32  
10
-5
  IPC 28.25 28.30 
10
-5
  IPC 28.34  
10
-5
  IPC 28.19 28.08 
10
-5
  IPC 27.96  
10
-5
  IPC 28.13 27.96 
10
-5
  IPC 27.80  
10
-5
  IPC 28.27 28.21 
10
-5
  IPC 28.15  
10
-5
  IPC 28.02 27.87 
10
-5
  IPC 27.71  
10
-5
  IPC 28.26 28.25 
10
-5
  IPC 28.25  
10
-3
  IPC 39.02 38.11 
10
-3
  IPC 37.20  
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Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
NTC  IPC 28.19 28.15 
NTC  IPC 28.11  
NAC  IPC Undetermined  
NAC  IPC Undetermined  
NTC  IPC 27.99 27.98 
NTC  IPC 27.97  
NAC  IPC Undetermined  
NAC  IPC Undetermined  
NTC  IPC 28.55 28.50 
NTC  IPC 28.46  
NAC  IPC Undetermined  
NAC  IPC Undetermined  
NTC  IPC 28.45 28.33 
NTC  IPC 28.21  
NAC  IPC Undetermined  
NAC  IPC Undetermined  
NTC  IPC 28.49 28.50 
NTC  IPC 28.52  
NAC  IPC Undetermined  
NAC  IPC Undetermined  
NTC  IPC 28.57 28.51 
NTC  IPC 28.44  
NAC  IPC Undetermined  
NAC  IPC Undetermined  
NTC  IPC 30.33 30.01 
NTC  IPC 29.69  
NAC  IPC Undetermined  
NAC  IPC Undetermined  
NTC  IPC 28.28 28.30 
NTC  IPC 28.31  
NAC  IPC Undetermined  
NAC  IPC Undetermined  
NTC  IPC 28.28 28.33 
NTC  IPC 28.38  
NAC  IPC Undetermined  
NAC  IPC Undetermined  
NTC  IPC 28.45 28.46 
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Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
NTC  IPC 28.46  
NAC  IPC Undetermined  
NAC  IPC Undetermined  
NTC  IPC 28.27 28.37 
NTC  IPC 28.47  
NAC  IPC Undetermined  
NAC  IPC Undetermined  
NTC  IPC 28.27 28.39 
NTC  IPC 28.50  
NAC  IPC Undetermined  
NAC  IPC Undetermined  
NTC  IPC 28.28 28.26 
NTC  IPC 28.24  
NAC  IPC Undetermined  
NAC  IPC Undetermined  
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Appendix F 
Clostridium difficile (Cdif) PCR Data  
(NAC = No amplification control, NTC = No template control, 10
-5
 = positive control)  
Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
4A 4 Cdif Undetermined  
4A 4 Cdif Undetermined  
5A 5 Cdif Undetermined  
5A 5 Cdif Undetermined  
6A 6 Cdif Undetermined  
6A 6 Cdif Undetermined  
8A 8 Cdif Undetermined  
8A 8 Cdif Undetermined  
8A (1:10) 8 Cdif Undetermined  
8A (1:10) 8 Cdif Undetermined  
9A 9 Cdif Undetermined  
9A 9 Cdif Undetermined  
9A (1:10) 9 Cdif Undetermined  
9A (1:10) 9 Cdif Undetermined  
10A 10 Cdif Undetermined  
10A 10 Cdif Undetermined  
10A (1:10) 10 Cdif Undetermined  
10A (1:10) 10 Cdif Undetermined  
11A 11 Cdif Undetermined  
11A 11 Cdif Undetermined  
11A (1:10) 11 Cdif 36.49 37.02 
11A (1:10) 11 Cdif 37.55  
11A (1:10) 11 Cdif 37.51 37.44 
11A (1:10) 11 Cdif 37.38  
13A 13 Cdif Undetermined  
13A 13 Cdif Undetermined  
14A 14 Cdif Undetermined  
14A 14 Cdif Undetermined  
14A (1:10) 14 Cdif Undetermined  
14A (1:10) 14 Cdif Undetermined  
4B 4 Cdif Undetermined  
4B 4 Cdif Undetermined  
4B (1:10) 4 Cdif Undetermined  
73 
 
Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
4B (1:10) 4 Cdif Undetermined  
5B 5 Cdif Undetermined  
5B 5 Cdif Undetermined  
6B 6 Cdif Undetermined  
6B 6 Cdif Undetermined  
7B 7 Cdif Undetermined  
7B 7 Cdif Undetermined  
7B (1:10) 7 Cdif Undetermined  
7B (1:10) 7 Cdif Undetermined  
8B 8 Cdif Undetermined  
8B 8 Cdif Undetermined  
8B (1:10) 8 Cdif Undetermined  
8B (1:10) 8 Cdif Undetermined  
9B 9 Cdif Undetermined  
9B 9 Cdif Undetermined  
9B (1:10) 9 Cdif Undetermined  
9B (1:10) 9 Cdif Undetermined  
10B 10 Cdif Undetermined  
10B 10 Cdif Undetermined  
10B (1:10) 10 Cdif Undetermined  
10B (1:10) 10 Cdif Undetermined  
11B 11 Cdif Undetermined  
11B 11 Cdif Undetermined  
11B (1:10) 11 Cdif Undetermined  
11B (1:10) 11 Cdif Undetermined  
13B 13 Cdif Undetermined  
13B 13 Cdif Undetermined  
14B 14 Cdif Undetermined  
14B 14 Cdif Undetermined  
14B (1:10) 14 Cdif Undetermined  
14B (1:10) 14 Cdif Undetermined  
4C 4 Cdif Undetermined  
4C 4 Cdif Undetermined  
5C 5 Cdif Undetermined  
5C 5 Cdif Undetermined  
6C 6 Cdif Undetermined  
6C 6 Cdif Undetermined  
74 
 
Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
7C 7 Cdif Undetermined  
7C 7 Cdif Undetermined  
7C (1:10) 7 Cdif Undetermined  
7C (1:10) 7 Cdif Undetermined  
8C 8 Cdif Undetermined  
8C 8 Cdif Undetermined  
8C (1:10) 8 Cdif Undetermined  
8C (1:10) 8 Cdif Undetermined  
9C 9 Cdif Undetermined  
9C 9 Cdif Undetermined  
9C (1:10) 9 Cdif Undetermined  
9C (1:10) 9 Cdif Undetermined  
10C 10 Cdif Undetermined  
10C 10 Cdif Undetermined  
10C (1:10) 10 Cdif Undetermined  
10C (1:10) 10 Cdif Undetermined  
11C 11 Cdif Undetermined  
11C 11 Cdif Undetermined  
11C (1:10) 11 Cdif Undetermined  
11C (1:10) 11 Cdif Undetermined  
14C 14 Cdif Undetermined  
14C 14 Cdif Undetermined  
14C (1:10) 14 Cdif Undetermined  
14C (1:10) 14 Cdif Undetermined  
4D 4 Cdif Undetermined  
4D 4 Cdif Undetermined  
4D (1:10) 4 Cdif Undetermined  
4D (1:10) 4 Cdif Undetermined  
5D 5 Cdif Undetermined  
5D 5 Cdif Undetermined  
6D 6 Cdif Undetermined  
6D 6 Cdif Undetermined  
7D 7 Cdif Undetermined  
7D 7 Cdif Undetermined  
7D (1:10) 7 Cdif Undetermined  
7D (1:10) 7 Cdif Undetermined  
8D 8 Cdif Undetermined  
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Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
8D 8 Cdif Undetermined  
8D (1:10) 8 Cdif Undetermined  
8D (1:10) 8 Cdif Undetermined  
9D 9 Cdif Undetermined  
9D 9 Cdif Undetermined  
9D (1:10) 9 Cdif Undetermined  
9D (1:10) 9 Cdif Undetermined  
10D 10 Cdif Undetermined  
10D 10 Cdif Undetermined  
10D (1:10) 10 Cdif Undetermined  
10D (1:10) 10 Cdif Undetermined  
11D 11 Cdif Undetermined  
11D 11 Cdif Undetermined  
14D 14 Cdif Undetermined  
14D 14 Cdif Undetermined  
14D (1:10) 14 Cdif Undetermined  
14D (1:10) 14 Cdif Undetermined  
4E 4 Cdif Undetermined  
4E 4 Cdif Undetermined  
5E 5 Cdif Undetermined  
5E 5 Cdif Undetermined  
6E 6 Cdif Undetermined  
6E 6 Cdif Undetermined  
7E 7 Cdif Undetermined  
7E 7 Cdif Undetermined  
9E 9 Cdif Undetermined  
9E 9 Cdif Undetermined  
10E 10 Cdif Undetermined  
10E 10 Cdif Undetermined  
10E (1:10) 10 Cdif Undetermined  
10E (1:10) 10 Cdif Undetermined  
11E 11 Cdif Undetermined  
11E 11 Cdif Undetermined  
11E (1:10) 11 Cdif Undetermined  
11E (1:10) 11 Cdif Undetermined  
14E 14 Cdif Undetermined  
14E 14 Cdif Undetermined  
76 
 
Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
14E (1:10) 14 Cdif Undetermined  
14E (1:10) 14 Cdif Undetermined  
4F 4 Cdif Undetermined  
4F 4 Cdif Undetermined  
4F 4 Cdif Undetermined  
4F 4 Cdif Undetermined  
5F 5 Cdif Undetermined  
5F 5 Cdif Undetermined  
5F (1:10) 5 Cdif Undetermined  
5F (1:10) 5 Cdif Undetermined  
6F 6 Cdif Undetermined  
6F 6 Cdif Undetermined  
6F (1:10) 6 Cdif Undetermined  
6F (1:10) 6 Cdif Undetermined  
7F 7 Cdif Undetermined  
7F 7 Cdif Undetermined  
7F (1:10) 7 Cdif Undetermined  
7F (1:10) 7 Cdif Undetermined  
8F 8 Cdif Undetermined  
8F 8 Cdif Undetermined  
8F (1:10) 8 Cdif Undetermined  
8F (1:10) 8 Cdif Undetermined  
9F 9 Cdif Undetermined  
9F 9 Cdif Undetermined  
10F 10 Cdif Undetermined  
10F 10 Cdif Undetermined  
10F (1:10) 10 Cdif Undetermined  
10F (1:10) 10 Cdif Undetermined  
11F 11 Cdif Undetermined  
11F 11 Cdif Undetermined  
11F (1:10) 11 Cdif 35.24 35.13 
11F (1:10) 11 Cdif 35.01  
11F (1:10) 11 Cdif 36.02 35.54 
11F (1:10) 11 Cdif 35.06  
13F 13 Cdif Undetermined  
13F 13 Cdif Undetermined  
14F 14 Cdif Undetermined  
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Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
14F 14 Cdif Undetermined  
14F (1:10) 14 Cdif Undetermined  
14F (1:10) 14 Cdif Undetermined  
4G 4 Cdif 36.90 37.22 
4G 4 Cdif 37.54  
4G 4 Cdif Undetermined  
4G 4 Cdif Undetermined  
4G 4 Cdif 39.29 39.08 
4G 4 Cdif 38.87  
5G 5 Cdif Undetermined  
5G 5 Cdif Undetermined  
6G 6 Cdif Undetermined  
6G 6 Cdif Undetermined  
7G 7 Cdif Undetermined  
7G 7 Cdif Undetermined  
7G (1:10) 7 Cdif Undetermined  
7G (1:10) 7 Cdif Undetermined  
7G (1:10) 7 Cdif Undetermined  
7G (1:10) 7 Cdif Undetermined  
8G 8 Cdif Undetermined  
8G 8 Cdif Undetermined  
8G (1:10) 8 Cdif Undetermined  
8G (1:10) 8 Cdif Undetermined  
9G 9 Cdif Undetermined  
9G 9 Cdif Undetermined  
9G (1:10) 9 Cdif Undetermined  
9G (1:10) 9 Cdif Undetermined  
10G 10 Cdif Undetermined  
10G 10 Cdif Undetermined  
10G (1:10) 10 Cdif Undetermined  
10G (1:10) 10 Cdif Undetermined  
11G 11 Cdif Undetermined  
11G 11 Cdif Undetermined  
11G (1:10) 11 Cdif Undetermined  
11G (1:10) 11 Cdif Undetermined  
13G 13 Cdif Undetermined  
13G 13 Cdif Undetermined  
78 
 
Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
14G 14 Cdif Undetermined  
14G 14 Cdif Undetermined  
14G (1:10) 14 Cdif Undetermined  
14G (1:10) 14 Cdif Undetermined  
14G (1:10) 14 Cdif Undetermined  
14G (1:10) 14 Cdif Undetermined  
4H 4 Cdif Undetermined  
4H 4 Cdif Undetermined  
4H (1:10) 4 Cdif Undetermined  
4H (1:10) 4 Cdif Undetermined  
5H 5 Cdif Undetermined  
5H 5 Cdif Undetermined  
5H (1:10) 5 Cdif Undetermined  
5H (1:10) 5 Cdif Undetermined  
8H 8 Cdif Undetermined  
8H 8 Cdif Undetermined  
8H (1:10) 8 Cdif Undetermined  
8H (1:10) 8 Cdif Undetermined  
9H 9 Cdif Undetermined  
9H 9 Cdif Undetermined  
9H (1:10) 9 Cdif Undetermined  
9H (1:10) 9 Cdif Undetermined  
10H 10 Cdif Undetermined  
10H 10 Cdif Undetermined  
10H (1:10) 10 Cdif Undetermined  
10H (1:10) 10 Cdif Undetermined  
11H 11 Cdif Undetermined  
11H 11 Cdif Undetermined  
11H (1:10) 11 Cdif Undetermined  
11H (1:10) 11 Cdif Undetermined  
13H 13 Cdif Undetermined  
13H 13 Cdif Undetermined  
4I 4 Cdif Undetermined  
4I 4 Cdif Undetermined  
4I (1:10) 4 Cdif Undetermined  
4I (1:10) 4 Cdif Undetermined  
5I 5 Cdif Undetermined  
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Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
5I 5 Cdif Undetermined  
6I 6 Cdif 39.13  
6I 6 Cdif Undetermined  
6I 6 Cdif 36.66 36.98 
6I 6 Cdif 37.29  
6I 6 Cdif 38.18 37.64 
6I 6 Cdif 37.09  
7I 7 Cdif Undetermined  
7I 7 Cdif Undetermined  
7I (1:10) 7 Cdif Undetermined  
7I (1:10) 7 Cdif Undetermined  
8I 8 Cdif Undetermined  
8I 8 Cdif Undetermined  
8I (1:10) 8 Cdif Undetermined  
8I (1:10) 8 Cdif Undetermined  
9I 9 Cdif Undetermined  
9I 9 Cdif Undetermined  
10I 10 Cdif Undetermined  
10I 10 Cdif Undetermined  
10I (1:10) 10 Cdif Undetermined  
10I (1:10) 10 Cdif Undetermined  
11I 11 Cdif Undetermined  
11I 11 Cdif Undetermined  
13I 13 Cdif Undetermined  
13I 13 Cdif Undetermined  
14I 14 Cdif Undetermined  
14I 14 Cdif Undetermined  
14I (1:10) 14 Cdif Undetermined  
14I (1:10) 14 Cdif Undetermined  
4J 4 Cdif Undetermined  
4J 4 Cdif Undetermined  
4J (1:10) 4 Cdif Undetermined  
4J (1:10) 4 Cdif Undetermined  
5J 5 Cdif Undetermined  
5J 5 Cdif Undetermined  
6J 6 Cdif Undetermined  
6J 6 Cdif Undetermined  
80 
 
Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
7J 7 Cdif Undetermined  
7J 7 Cdif Undetermined  
7J (1:10) 7 Cdif Undetermined  
7J (1:10) 7 Cdif Undetermined  
8J 8 Cdif Undetermined  
8J 8 Cdif Undetermined  
8J (1:10) 8 Cdif Undetermined  
8J (1:10) 8 Cdif Undetermined  
9J 9 Cdif Undetermined  
9J 9 Cdif Undetermined  
9J (1:10) 9 Cdif Undetermined  
9J (1:10) 9 Cdif Undetermined  
10J 10 Cdif Undetermined  
10J 10 Cdif Undetermined  
10J (1:10) 10 Cdif Undetermined  
10J (1:10) 10 Cdif Undetermined  
11J 11 Cdif Undetermined  
11J 11 Cdif Undetermined  
14J 14 Cdif Undetermined  
14J 14 Cdif Undetermined  
14J (1:10) 14 Cdif Undetermined  
14J (1:10) 14 Cdif Undetermined  
4K 4 Cdif Undetermined  
4K 4 Cdif Undetermined  
4K (1:10) 4 Cdif Undetermined  
4K (1:10) 4 Cdif Undetermined  
5K 5 Cdif Undetermined  
5K 5 Cdif Undetermined  
5K (1:10) 5 Cdif Undetermined  
5K (1:10) 5 Cdif Undetermined  
6K 6 Cdif Undetermined  
6K 6 Cdif Undetermined  
7K 7 Cdif Undetermined  
7K 7 Cdif Undetermined  
7K (1:10) 7 Cdif Undetermined  
7K (1:10) 7 Cdif Undetermined  
8K 8 Cdif Undetermined  
81 
 
Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
8K 8 Cdif Undetermined  
9K 9 Cdif Undetermined  
9K 9 Cdif Undetermined  
10K 10 Cdif Undetermined  
10K 10 Cdif Undetermined  
10K (1:10) 10 Cdif Undetermined  
10K (1:10) 10 Cdif Undetermined  
11K 11 Cdif Undetermined  
11K 11 Cdif Undetermined  
14K 14 Cdif Undetermined  
14K 14 Cdif Undetermined  
14K (1:10) 14 Cdif Undetermined  
14K (1:10) 14 Cdif Undetermined  
4L 4 Cdif Undetermined  
4L 4 Cdif Undetermined  
5L 5 Cdif Undetermined  
5L 5 Cdif Undetermined  
5L (1:10) 5 Cdif Undetermined  
5L (1:10) 5 Cdif Undetermined  
6L 6 Cdif Undetermined  
6L 6 Cdif Undetermined  
7L 7 Cdif Undetermined  
7L 7 Cdif Undetermined  
7L (1:10) 7 Cdif Undetermined  
7L (1:10) 7 Cdif Undetermined  
9L 9 Cdif Undetermined  
9L 9 Cdif Undetermined  
10L 10 Cdif Undetermined  
10L 10 Cdif Undetermined  
10L (1:10) 10 Cdif Undetermined  
10L (1:10) 10 Cdif Undetermined  
11L 11 Cdif Undetermined  
11L 11 Cdif Undetermined  
11L (1:10) 11 Cdif Undetermined  
11L (1:10) 11 Cdif Undetermined  
14L 14 Cdif Undetermined  
14L 14 Cdif Undetermined  
82 
 
Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
14L (1:10) 14 Cdif Undetermined  
14L (1:10) 14 Cdif Undetermined  
4M 4 Cdif Undetermined  
4M 4 Cdif Undetermined  
4M 4 Cdif Undetermined  
4M 4 Cdif Undetermined  
5M 5 Cdif Undetermined  
5M 5 Cdif Undetermined  
5M (1:10) 5 Cdif Undetermined  
5M (1:10) 5 Cdif Undetermined  
6M 6 Cdif Undetermined  
6M 6 Cdif Undetermined  
6M (1:10) 6 Cdif 39.30  
6M (1:10) 6 Cdif Undetermined  
6M (1:10) 6 Cdif 38.65  
6M (1:10) 6 Cdif Undetermined  
7M 7 Cdif Undetermined  
7M 7 Cdif Undetermined  
7M (1:10) 7 Cdif Undetermined  
7M (1:10) 7 Cdif Undetermined  
8M 8 Cdif Undetermined  
8M 8 Cdif Undetermined  
8M (1:10) 8 Cdif Undetermined  
8M (1:10) 8 Cdif Undetermined  
9M 9 Cdif Undetermined  
9M 9 Cdif Undetermined  
9M (1:10) 9 Cdif Undetermined  
9M (1:10) 9 Cdif Undetermined  
10M 10 Cdif Undetermined  
10M 10 Cdif Undetermined  
10M (1:10) 10 Cdif Undetermined  
10M (1:10) 10 Cdif Undetermined  
11M 11 Cdif Undetermined  
11M 11 Cdif Undetermined  
13M 13 Cdif Undetermined  
13M 13 Cdif Undetermined  
14M 14 Cdif Undetermined  
83 
 
Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
14M 14 Cdif Undetermined  
14M (1:10) 14 Cdif Undetermined  
14M (1:10) 14 Cdif Undetermined  
4N 4 Cdif Undetermined  
4N 4 Cdif Undetermined  
4N (1:10) 4 Cdif Undetermined  
4N (1:10) 4 Cdif Undetermined  
5N 5 Cdif Undetermined  
5N 5 Cdif Undetermined  
5N (1:10) 5 Cdif Undetermined  
5N (1:10) 5 Cdif Undetermined  
6N 6 Cdif Undetermined  
6N 6 Cdif Undetermined  
7N 7 Cdif Undetermined  
7N 7 Cdif Undetermined  
7N (1:10) 7 Cdif Undetermined  
7N (1:10) 7 Cdif Undetermined  
8N 8 Cdif Undetermined  
8N 8 Cdif Undetermined  
8N (1:10) 8 Cdif Undetermined  
8N (1:10) 8 Cdif Undetermined  
9N 9 Cdif Undetermined  
9N 9 Cdif Undetermined  
9N (1:10) 9 Cdif Undetermined  
9N (1:10) 9 Cdif Undetermined  
10N 10 Cdif Undetermined  
10N 10 Cdif Undetermined  
10N (1:10) 10 Cdif Undetermined  
10N (1:10) 10 Cdif Undetermined  
11N 11 Cdif 22.76 26.32 
11N 11 Cdif 29.87  
11N 11 Cdif Undetermined  
11N 11 Cdif Undetermined  
11N (1:10) 11 Cdif Undetermined  
11N (1:10) 11 Cdif Undetermined  
13N 13 Cdif Undetermined  
13N 13 Cdif Undetermined  
84 
 
Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
14N 14 Cdif Undetermined  
14N 14 Cdif Undetermined  
14N (1:10) 14 Cdif Undetermined  
14N (1:10) 14 Cdif Undetermined  
10
-5
  Cdif 29.35 29.53 
10
-5
  Cdif 29.71  
10
-5
  Cdif 28.77 28.84 
10
-5
  Cdif 28.91  
10
-5
  Cdif 29.14 29.15 
10
-5
  Cdif 29.16  
10
-5
  Cdif 29.35 29.39 
10
-5
  Cdif 29.42  
10
-5
  Cdif 29.41 29.43 
10
-5
  Cdif 29.45  
10
-5
  Cdif 29.45 29.48 
10
-5
  Cdif 29.50  
10
-5
  Cdif 29.12 29.24 
10
-5
  Cdif 29.36  
10
-5
  Cdif 28.80 28.74 
10
-5
  Cdif 28.69  
10
-5
  Cdif 29.61 29.34 
10
-5
  Cdif 29.07  
10
-5
  Cdif 28.39 28.47 
10
-5
  Cdif 28.56  
10
-5
  Cdif 28.57 28.53 
10
-5
  Cdif 28.49  
10
-5
  Cdif 28.27 28.35 
10
-5
  Cdif 28.44  
10
-3
  Cdif 20.57 20.56 
10
-3
  Cdif 20.54  
NTC  Cdif Undetermined  
NTC  Cdif Undetermined  
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Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
NAC  Cdif Undetermined  
NAC  Cdif Undetermined  
NTC  Cdif Undetermined  
NTC  Cdif Undetermined  
NAC  Cdif Undetermined  
NAC  Cdif Undetermined  
NTC  Cdif Undetermined  
NTC  Cdif Undetermined  
NAC  Cdif Undetermined  
NAC  Cdif Undetermined  
NTC  Cdif Undetermined  
NTC  Cdif Undetermined  
NAC  Cdif Undetermined  
NAC  Cdif Undetermined  
NTC  Cdif Undetermined  
NTC  Cdif Undetermined  
NAC  Cdif Undetermined  
NAC  Cdif Undetermined  
NTC  Cdif Undetermined  
NTC  Cdif Undetermined  
NAC  Cdif Undetermined  
NAC  Cdif Undetermined  
NTC  Cdif Undetermined  
NTC  Cdif Undetermined  
NAC  Cdif Undetermined  
NAC  Cdif Undetermined  
NTC  Cdif Undetermined  
NTC  Cdif Undetermined  
NAC  Cdif Undetermined  
NAC  Cdif Undetermined  
NTC  Cdif Undetermined  
NTC  Cdif Undetermined  
NAC  Cdif Undetermined  
NAC  Cdif Undetermined  
NTC  Cdif Undetermined  
NTC  Cdif Undetermined  
NAC  Cdif Undetermined  
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Location Site 
number 
Detector 
name 
Ct Mean 
Ct 
NAC  Cdif Undetermined  
NTC  Cdif Undetermined  
NTC  Cdif Undetermined  
NAC  Cdif Undetermined  
NAC  Cdif Undetermined  
NTC  Cdif Undetermined  
NTC  Cdif Undetermined  
NAC  Cdif Undetermined  
NAC  Cdif Undetermined  
NTC  Cdif Undetermined  
NTC  Cdif Undetermined  
NAC  Cdif Undetermined  
NAC  Cdif Undetermined  
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